compounds
Selective TrkB PAMs enhance neuroplasticity by modulating TrkB responsiveness to endogenous BDNF, addressing the limitations of existing therapies and ensuring safety and efficacy in treating disorders related to TrkB dysregulation.
Patent Information
- Application Number
- PCT/EP2026/063499
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapeutic strategies targeting TrkB signaling, such as BDNF mimetics and TrkB agonists, face challenges with poor pharmacokinetics, broad activity profiles, and risks of maladaptive synaptic plasticity, while psychedelic compounds have psychotropic liabilities that limit their clinical adoption.
Development of selective TrkB PAMs that enhance receptor responsiveness to endogenous BDNF without activating it independently, thereby promoting neuroplasticity while avoiding serotonin 2A receptor engagement and hallucinogenic effects.
These compounds provide safe and effective neuroplasticity enhancement, applicable across various disorders, minimizing risks of maladaptive plasticity and psychotropic side effects, and expanding therapeutic applicability to broader patient populations.
Smart Images

Figure EP2026063499_12112026_PF_FP_ABST
Abstract
Description
COMPOUNDS
[0001] The present disclosure is directed to compounds which can induce neuronal plasticity, compositions comprising such compounds, methods for inducing neuroplasticity and compounds for use in such methods. Compounds of the invention can induce neuronal plasticity processes through modulation of the tropomyosin receptor kinase B (TrkB or NTRK2). Compounds of the invention can induce neuronal plasticity processes without mediating the serotonin 2A (5-HT2A) receptor, which is known to cause undesirable hallucinations.BACKGROUND
[0002] Tropomyosin receptor kinase B (TrkB) is a high-affinity receptor for brain-derived neurotrophic factor (BDNF), a key neurotrophin involved in synaptic plasticity, neuronal survival, learning, memory and cognitive function. TrkB-mediated signaling plays a central role in neurodevelopment and neuroplasticity (Park & Poo, 2013; Lu etal., 2013).
[0003] TrkB activation through BDNF binding initiates neurotrophic downstream signaling cascades including the MAPK / ERK, PI3K / Akt, and PLCy pathways, all of which regulate synaptic strength, dendritic spine morphology, and long-term potentiation (LTP), crucial processes underlying learning and memory (Yamada & Nabeshima, 2003; Minichiello, 2009). Disruptions in TrkB signaling impair experience-dependent plasticity, which is essential during both development and adulthood (Lu et al., 2005).
[0004] Alterations in BDNF-TrkB signaling have been observed in major depressive disorder, anxiety disorders, and bipolar disorder. Reduced BDNF levels and impaired TrkB activity correlate with depressive symptoms and treatment resistance (Duman & Monteggia, 2006). Antidepressants such as SSRIs and ketamine exert therapeutic effects through the upregulation of BDNF and activation of TrkB (Autry & Monteggia, 2012; Castren & Antila, 2017).
[0005] Neurodevelopmental conditions such as autism spectrum disorders (ASD) and intellectual disabilities exhibit aberrant TrkB-related pathways. Genetic and epigenetic alterations in the BDNF-TrkB axis can lead to disrupted cortical development and synaptogenesis, contributing to behavioral and cognitive impairments (Numakawa et al., 2017).
[0006] Impaired TrkB function has been noted in developmental syndromes such as Rett syndrome, where BDNF deficits contribute to cognitive and motor impairments (Chang et al., 2006; Zoghbi, 2003).
[0007] Following traumatic brain injury (TBI), TrkB expression is dynamically regulated. Upregulation of BDNF-TrkB is associated with both adaptive plasticity and maladaptivehyperexcitability, depending on timing and context (Binder et al., 2001; McNamara & Scharfman, 2012).
[0008] Recent advances building on the role of TrkB in neuroplasticity have revealed a common mechanism underlying the therapeutic effects of antidepressants and psychedelics. Traditionally, the efficacy of antidepressants was attributed to their modulation of monoaminergic systems, with the TrkB-mediated neuroplastic effects being considered downstream consequences. However, Casarotto et al. have demonstrated that a wide range of antidepressants — including SSRIs, tricyclics, and ketamine — directly bind to the transmembrane domain of the TrkB receptor, functioning as positive allosteric modulators (PAMs) (Casarotto et al., 2021; Moliner et al., 2023).
[0009] This direct interaction with TrkB facilitates its surface localization and enhances its activation by BDNF, thereby promoting synaptic plasticity independently of serotonin transporter or NMDA receptor modulation (Casarotto et al., 2021). Molecular dynamics simulations and structural biology studies have shown that antidepressants stabilize the TrkB transmembrane domain (TMD) dimer in a conformation favorable for BDNF signaling, suggesting that TrkB is not merely a downstream effector but a primary target for antidepressant action (Casarotto et al., 2021; Moliner et al., 2023; Enkavi et al., 2023; Kot et al., 2024).
[0010] Expanding on this paradigm, another landmark study revealed that psychedelics such as lysergic acid diethylamide (LSD) and psilocin also bind directly to the TMD of TrkB with exceptionally high affinity — up to 1,000 times greater than typical antidepressants (Moliner et al., 2023). These compounds act as TrkB PAMs by stabilizing the TMD dimer in a conformation that enhances responsiveness to endogenous BDNF, thus promoting robust and sustained neuroplastic changes.
[0011] Crucially, the antidepressant and plasticity-promoting effects of psychedelics are mediated through TrkB and are mechanistically dissociable from their hallucinogenic properties, which are driven by serotonin 2A (5-HT2A) receptor activation. Indeed, while psychedelics like LSD induce behavioral and neuronal plasticity via TrkB activation, their hallucinogenic effects are entirely dependent on 5-HT2A signaling and independent of TrkB (Moliner et al., 2023). A recent case report with a depression patient treated with psilocybin in a clinical trial that was also being treated with a 5-HT2A receptor antagonist illustrates that this might also be the case in humans, as the patient displayed a fast and long-lasting antidepressant response without experiencing the hallucinations that characterize psychedelics (Rosenblat et al., 2023).
[0012] This understanding sets the stage for a new class of TrkB PAM neurotherapeutics. By targeting the transmembrane allosteric site on TrkB, it is now possible to pursue the development of compounds that retain the rapid and durable therapeutic benefits observed with psychedelics but are devoid of their psychotropic liabilities — thereby overcoming a major obstacle to the widespread clinical adoption of psychedelic-based treatments (Enkavi et al., 2023; Moliner et al., 2023). As such, promotion of neuroplasticity through TrkB allosteric modulation represents a unifying mechanism across pharmacologically diverse therapeutics and a promising frontier for precision drug development in any disorders that involve BDNF and TrkB neurotrophic signaling dysregulation.
[0013] While BDNF mimetics and direct TrkB agonists have long been explored as therapeutic strategies, their clinical development has faced substantial obstacles. BDNF itself, as a large and unstable peptide, has poor pharmacokinetics and bioavailability, making systemic delivery challenging. Moreover, due to its broad activity profile, exogenous BDNF or small molecule BDNF mimetics can indiscriminately activate all TrkB receptors, which are widely expressed in the brain, potentially interfering with normal receptor function and offsetting the necessary activity-dependent fine-tuning of synapses and neuronal networks (Enkavi et al., 2023). Similarly, engineered TrkB agonist antibodies, though promising in neurodegenerative contexts, typically act with high potency and low selectivity in terms of spatial and temporal resolution, risking receptor desensitization or non-physiological activation that could disrupt synaptic homeostasis (Enkavi et al., 2023).
[0014] In contrast, selective TrkB PAMs offer several pharmacological advantages. Unlike orthosteric agonists, PAMs do not activate the receptor independently; instead, they enhance the receptor's responsiveness to endogenous BDNF in an activity-dependent manner. This preserves the natural spatial and temporal dynamics of TrkB signaling, which is tightly regulated by neuronal activity and synaptic localization. Such modulation ensures plasticity is enhanced only when and where it is needed, minimizing risks of maladaptive synaptic plasticity and neuronal network remodeling (Enkavi et al., 2023; Moliner et al., 2023; Casarotto et al., 2021).
[0015] Furthermore, a highly selective TrkB PAM lacking5-HT2Aand other off-target activities avoids the major limitations associated with psychedelic compounds. By eliminating 5-HT2A receptor engagement, these compounds can bypass hallucinogenic effects, risks of developing irreversible psychosis or hallucinogen persisting perception disorder (HPPD), and the need for intensive clinical monitoring that currently restricts the use of psychedelics in mental health care (Moliner et al., 2023). This pharmacological precision not only enhancessafety and efficacy but also expands the therapeutic applicability of TrkB-targeting drugs across broader patient populations, including those with comorbidities or vulnerability to serotonin-related adverse effects. In this light, the design of selective TrkB PAMs represents a rational and promising therapeutic direction, balancing efficacy, safety, and physiologically relevant modulation of neuroplasticity.ReferencesAutry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012 Apr;64(2):238-58. doi: 10.1124 / pr.111.005108. Epub 2012 Mar 8. PMID: 22407616; PMCID: PMC3310485.Binder DK, Croll SD, Gall CM, Scharfman HE. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 2001 Jan;24(1):47-53. doi: 10.1016 / s0166-2236(00)01682-9. PMID: 11163887.Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, Biojone C, Cannarozzo C, Sahu MP, Kaurinkoski K, Brunello CA, Steinzeig A, Winkel F, Patil S, Vestring S, SerchovT, Diniz CRAF, Laukkanen L, Cardon I, Antila H, RogT, Piepponen TP, Bramham CR, Normann C, Lauri SE, Saarma M, Vattulainen I, Castren E. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021 Mar 4;184(5):1299-1313.e19. doi: 10.1016 / j.cell.2021.01.034. Epub 2021 Feb 18. PMID: 33606976; PMCID: PMC7938888.Castren E, Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry. 2017 Aug;22(8):1085-1095. doi: 10.1038 / mp.2017.61. Epub 2017 Apr 11. PMID: 28397840; PMCID: PMC5510719.Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006 Feb 2;49(3):341-8. doi: 10.1016 / j. neuron.2005.12.027. PMID: 16446138.Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006 Jun 15;59(12):1116-27. doi: 10.1016 / j. biopsych.2006.02.013. Epub 2006 Apr 21. PMID: 16631126.Enkavi G, Girych M, Moliner R, Vattulainen I, Castren E. TrkB transmembrane domain: bridging structural understanding with therapeutic strategy. Trends Biochem Sci. 2024 May;49(5):445-456. doi: 10.1016 / j.tibs.2024.02.001. Epub 2024 Mar 2. PMID: 38433044.Kot EF, Goncharuk SA, Franco ML, McKenzie DM, Arseniev AS, Benito-Martinez A, Costa M, Cattaneo A, Hristova K, Vilar M, Mineev KS. Structural basis for the transmembrane signalingand antidepressant-induced activation of the receptor tyrosine kinase TrkB. Nat Commun.2024 Oct 29;15(1):9316. doi: 10.1038 / S41467-024-53710-7. PMID: 39472452; PMCID: PMC11522581.Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a diseasemodifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013 Jun;14(6):401-16. doi: 10.1038 / nrn3505. Epub 2013 May 15. PMID: 23674053.Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005 Aug;6(8):603-14. doi: 10.1038 / nrn1726. PMID: 16062169.McNamara JO, Scharfman HE. Temporal Lobe Epilepsy and the BDNF Receptor, TrkB. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PMID: 22787630.Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci. 2009 Dec;10(12):850-60. doi: 10.1038 / nrn2738. PMID: 19927149.Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsila LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Ohman T, RogT, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castren E. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023 Jun;26(6):1032-1041. doi: 10.1038 / s41593-023-01316-5. Epub 2023 Jun 5. PMID: 37280397; PMCID: PMC10244169.Numakawa T, Odaka H, Adachi N. Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis. Int J Mol Sci. 2017 Nov 2;18(11):2312. doi: 10.3390 / ijms18112312. PMID: 29099059; PMCID: PMC5713281.Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013 Jan;14(1):7-23. doi: 10.1038 / nrn3379. PMID: 23254191.Rosenblat JD, Leon-Carlyle M, Ali S, Husain Ml, McIntyre RS. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. Am J Psychiatry. 2023 May 1;180(5):395-396. doi: 10.1176 / appi.ajp.20220835. Epub 2023 Mar 22. PMID: 36945824.Yamada K, Nabeshima T. Brain-derived neurotrophic factor / TrkB signaling in memory processes. J Pharmacol Sci. 2003 Apr;91(4):267-70. doi: 10.1254 / jphs.91.267. PMID: 12719654.Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science. 2003 Oct 31;302(5646):826-30. doi: 10.1126 / science.1089071. PMID: 14593168.BRIEF SUMMARY OF THE DISCLOSURE
[0016] In accordance with the present invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof:, 5- to 6-membered heteroaryl, and -C(O)NR1aR1b;whereinR1aand R1bare each independently selected from: H, C1-6alkyl, and C1-6haloalkyl;Z1and Z4are each nitrogen, andZ2, Z3, Z5, and Z6are independently selected from: a bond, carbon, nitrogen, and oxygen;wherein said, and 5- to 6-membered heteroaryl are optionally substituted by one or more R2;R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a;X1is selected from: a bond, -O-, -NR3-, and -S(O)X-,wherein R3is independently selected from: deuterium, H, Ci-6alkyl, Ci-6haloalkyl, C3- 6 cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-Ci-6alkyl;L is selected from: C1-8alkylene and -C(O)-;wherein said C1-8alkylene is optionally substituted by one or more R4;R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR4a, -C(O)R4a, -OC(O)R4a, -C(O)OR4a;X2is selected from: -O-, and -S(O)X-;Ring A is a 5- or 6-membered heterocycloalkyl or 5- or 6-membered heterocycloalkenyl, wherein one of A1and A2is selected from a bond, carbon and nitrogen and the other of A1and A2is carbon or nitrogen, and A3is carbon or nitrogen;wherein Ring A is optionally substituted by one or more R5;R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a;Ring B is 5- or 6-membered heteroaryl, wherein one of B1and B2is selected from: a bond, carbon and nitrogen, and the other of B1and B2is selected from: carbon and nitrogen, wherein said 5- or 6-membered heteroaryl is optionally substituted by one or more R6:R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1_6alkyl, C1_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a;Ring C is selected from: 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl,wherein said 4- to 7-membered heterocycloalkyl, 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, and 5- to 7-membered heterocycloalkenyl are optionally substituted by one or more R7, and said phenyl and 5- or 6-membered heteroaryl are optionally substituted by one or more R8;R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a;R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a;R2a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: deuterium, H, C1-6alkyl, C1-6 haloalkyl, C3-6cycloalkyl, and 4- to 6-membered heterocycloalkyl;R2b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: deuterium, H, C1-6alkyl, C1-6 haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-C1-6alkyl;or wherein, at each occurrence, R2aand R2b, R4aand R4b, R5aand R5b, R6aand R6b, R7aand R7b, or R8aand R8b, togetherwith the nitrogen atom to which they are attached, mayform a 4-6-membered heterocycloalkyl ring;each x is independently 0, 1, or 2;wherein any of the aforementioned alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, phenyl, or heteroaryl groups is optionally substituted, where chemically possible, by one or more substituents independently at each occurrence selected from the group consisting of: C1-6alkyl, C1_6alkyl-ORa, deuterium, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra; wherein Rais independently at each occurrence selected from H, and C1-4 alkyl; and Rbis independently at each occurrence selected from H, C1-4alkyl, C(O)-C1-4alkyl and S(O)2-C1-4alkyl; andwherein the compound according to formula (I) is not a compound selected from List A:List A
[0017] Also provided is a pharmaceutical composition comprising a compound of the invention, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient. In an embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.
[0018] Also provided is a compound of the invention, exceptthatthe compounds of List A a re not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament. In an embodiment, there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament.
[0019] Also provided is a compound of the invention, exceptthatthe compounds of List A a re not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2). In an embodiment, there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2).
[0020] Also provided is a method of treating a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof. In an embodiment, there is provided a method of treating a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof.
[0021] Also provided is a compound of the invention, except that the compounds of List A a re not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use in thetreatment of a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI). In an embodiment, there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in treating autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI).
[0022] Also provided is a method of treating a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI), the method comprising administering to a subject in need thereof, an effective amount of a compound of the invention, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof. In an embodiment is a method of treating a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI), the method comprising administeringto a subject in need thereof, an effective amount of a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof.DETAILED DESCRIPTION
[0023] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below.
[0024] Reference herein to a “compound of the invention” is a reference to any of the compounds disclosed herein including compounds any of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), or (IX), a compound selected from List A, or a compound described in any of the Examples, or a pharmaceutically acceptable salt and / or solvate thereof.
[0025] The terms “treating”, or “treatment” refer to any beneficial effect in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; modifying the progression of a disease or condition, making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric examinations, and / or a psychiatric evaluation. The term "treating" and conjugations thereof, includes prevention of an injury, pathology, condition, or disease (i.e., prophylaxis or prevention). For example, the term "treating" and conjugations thereof, include prevention of a pathology, condition, or disease associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) (e.g., reducing or preventing symptoms or effects of the disease or condition or preventing or inhibiting progression of the disease or condition.
[0026] The term “associated” or “associated with”, “involving” or “mediated by” in the context of TrkB or NTRK2 means that the disease is caused by (in whole or in part), ora symptom of the disease is caused by (in whole or in part) dysregulation of TrkB or NTRK2. A disease or medical disorder associated with dysregulation of T rkB or NTRK2, may be treated with a compound of the invention effective forstabilizingtheTrkB transmembrane domain dimer in a conformation favorable for BDNF signaling.
[0027] An “effective amount” is an amount sufficient to accomplish a stated purpose. For example an amount sufficient to achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce receptor signalling, increase receptor signalling, reduce one or more symptoms of a disease or condition, or to provide a disease modifying effect (i.e. alter the underlying pathophysiology of the disease). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, or modify the progression of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology, or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarilyoccur by administration of one dose and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. The exact amounts will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
[0028] The therapeutically effective amount of a compound of the invention can be initially estimated from the assays described herein. Target concentrations will be those concentrations of active compound(s) that are capable of achieving the therapeutic effect described herein, as measured using the methods described herein or known in the art.
[0029] Therapeutically effective amounts for use in humans can also be determined from animal models using known methods. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring compound effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
[0030] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
[0031] Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated, or in response to a biomarker or other correlate or surrogate end-point of the disease. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
[0032] A prophylactic or therapeutic treatment regimen is suitably one that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient. This determination of a dosage regimen is generally based upon an assessment of the active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.
[0033] The term “halo” or “halogen” refers to one of the halogens, group 7 of the periodic table. In particular the term refers to fluorine, chlorine, bromine and iodine. Preferably, the term refers to fluorine or chlorine.
[0034] The term Cm-nrefers to a group with m to n carbon atoms.
[0035] The term “Ci-ealkyl” refers to a linear or branched hydrocarbon chain containing 1, 2, 3, 4, 5 or 6 carbon atoms, for example methyl, ethyl, n-propyl, / so-propyl, n-butyl, / so-butyl, secbutyl, tert-butyl, n-pentyl and n-hexyl. “Ci-4alkyl” similarly refers to such groups containing up to 4 carbon atoms. Alkylene groups are divalent alkyl groups and may likewise be linear or branched and have two points of attachment to the remainder of the molecule. Furthermore, an alkylene group may, for example, correspond to one of those alkyl groups listed in this paragraph. For example, Ci_6alkylene may be -CH2-, -CH2CH2-, -CH2CH(CH3)-, -CH2CH2CH2-or -CH2CH(CH3)CH2-. The alkyl and alkylene groups may be unsubstituted or substituted by one or more substituents. Possible substituents are described herein. For example, substituents for an alkyl or alkylene group may be halogen, e.g. fluorine, chlorine, bromine and iodine, OH, Ci-C4alkoxy, -NR’R” amino, wherein R’ and R” are independently H or alkyl. Other substituents for the alkyl group may alternatively be used.
[0036] The term “Ci.6haloalkyl”, e.g., “Ci-4haloalkyl”, refers to a hydrocarbon chain substituted with at least one halogen atom independently chosen at each occurrence, for example fluorine, chlorine, bromine, and iodine. The halogen atom may be present at any position on the hydrocarbon chain. For example, Ci.6haloalkyl may refer to chloromethyl, fluoromethyl, trifluoromethyl, chloroethyl e.g., 1 -chloromethyl and 2-chloroethyl, trichloroethyl e.g., 1,2,2-trichloroethyl, 2,2,2-trichloroethyl, fluoroethyl e.g., 1 -fluoromethyl and 2-fluoroethyl, trifluoroethyl e.g., 1,2,2-trifluoroethyl and 2,2,2-trifluoroethyl, chloropropyl, trichloropropyl, fluoropropyl, trifluoropropyl. A haloalkyl group may be, for example, -CX3, -CHX2, -CH2CX3, -CH2CHX2or -CX(CH3)CH3wherein X is a halo (e.g., F, Cl, Br, or I). A fluoroalkyl group, i.e., a hydrocarbon chain substituted with at least one fluorine atom (e.g., -CF3, -CHF2, -CH2CF3or-CH2CHF2).
[0037] The term “heteroalkyl,” refers to a stable linear or branched chain alkyl, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group. The heteroalkyl is a non-cyclic group. “2 to 8 membered heteroalkyl” refers to a heteroalkyl in which there are a total of 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and heteroatoms (e.g., O, N, P, Si, and S) in the heteroalkyl group. Examples include, but are not limited to: -CH2-O-CH3,-CH2-CH2-O-CH3, -CH2-NH-CH3,-CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-S(O)-CH3, -CH2-S(O)2-CH3, -CH2-CH2-S-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH2-CH=N-OCH3, Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3and -CH2-O-Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P).
[0038] The term “C2.6alkenyl” includes a branched or linear hydrocarbon chain containing at least one double bond and having 2, 3, 4, 5 or 6 carbon atoms. The double bond(s) may be present as the E or Z isomer. The double bond may be at any possible position of the hydrocarbon chain. For example, the “C2.6alkenyl” may be ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl. Alkenylene groups are divalent alkenyl groups and may likewise be linear or branched and have two points of attachment to the remainder of the molecule. Furthermore, an alkenylene group may, for example, correspond to one of those alkenyl groups listed in this paragraph. For example, alkenylene may be -CH=CH-, -CH2CH=CH-, -CH(CH3)CH=CH- or -CH2CH=CH-. Alkenyl and alkenylene groups may unsubstituted or substituted by one or more substituents. Possible substituents are described herein. Forexample, substituents may be those described above as substituents for alkyl groups.
[0039] The term “C2.6alkynyl” includes a branched or linear hydrocarbon chain containing at least one triple bond and having 2, 3, 4, 5 or 6 carbon atoms. The triple bond may be at any possible position of the hydrocarbon chain. For example, the “C2.6alkynyl” may be ethynyl, propynyl, butynyl, pentynyl and hexynyl. Alkynylene groups are divalent alkynyl groups and may likewise be linear or branched and have two points of attachment to the remainder of the molecule. Furthermore, an alkynylene group may, for example, correspond to one of those alkynyl groups listed in this paragraph. For example alkynylene may be -C=C-, -CH2C=C-, -CH2C=CCH2-, -CH(CH3)CH=C- or -CH2C=CCH3. Alkynyl and alkynylene groups may unsubstituted or substituted by one or more substituents. Possible substituents are described herein. For example, substituents may be those described above as substituents for alkyl groups.
[0040] The term “C3.6cycloalkyl” includes a saturated hydrocarbon ring system containing 3, 4, 5 or 6 carbon atoms. For example, the “C3-C6cycloalkyl” may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.1.1]hexane or bicyclo[1.1.1]pentane. Suitably the “C3-C6cycloalkyl” may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0041] The term “heterocyclyl”, “heterocyclic” or “heterocycle” includes a non-aromatic saturated or partially saturated monocyclic orfused, bridged, orspiro bicyclic heterocyclic ring system. Monocyclic heterocyclic rings may contain from about 3 to 12 (suitably from 3 to 7) ring atoms, with from 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles may contain from 7 to 12-member atoms in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. The heterocyclyl group may be a 3-12, for example, a 3- to 9- (e.g. a 3- to 7-) membered non-aromatic monocyclic or bicyclic saturated or partially saturated group comprising 1, 2 or 3 heteroatoms independently selected from O, S and N in the ring system (in other words 1, 2 or 3 of the atoms forming the ring system are selected from O, S and N). By partially saturated it is meant that the ring may comprise one or two double bonds. This applies particularly to monocyclic rings with from 5 to 7 members. The double bond will typically be between two carbon atoms but may be between a carbon atom and a nitrogen atom. Bicyclic systems may be spiro-fused, i.e. where the rings are linked to each other through a single carbon atom; vicinally fused, i.e. where the rings are linked to each other through two adjacent carbon and / or nitrogen atoms; or they may be share a bridgehead, i.e. the rings are linked to each other through two non-adjacent carbon or nitrogen atoms (a bridged ring system). Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetra hydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles comprising at least one nitrogen in a ring position include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrotriazinyl, tetra hydropyrazolyl, tetrahydropyridinyl, homopiperidinyl, homopiperazinyl, 2,5-diaza-bicyclo[2.2.1]heptanyl and the like. Typical sulfur containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepine. Other heterocycles include dihydro oxathiolyl, tetrahydro oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydro oxazinyl, tetrahydropyrimidinyl, dioxolinyl, octa hydro benzofuranyl,octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl such as tetra hydrothiene 1,1 -dioxide and thiomorpholinyl 1,1 -dioxide. A suitable value for a heterocyclyl group which bears 1 or 2 oxo (=O), for example, 2 oxopyrrolidinyl, 2-oxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example azetidinyl, tetra hydrofuranyl, tetra hydropyranyl, pyrrolidinyl, morpholinyl, tetra hydrothienyl, tetrahydrothienyl 1,1 -dioxide, thiomorpholinyl, thiomorpholinyl 1,1 -dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person will appreciate, any heterocycle may be linked to another group via any suitable atom, such as via a carbon or nitrogen atom. For example, the term “piperidino” or “morpholino” refers to a piperidin-1-ylor morpholin-4-yl ring that is linked via the ring nitrogen.
[0042] The term “heterocyclyl”, “heterocyclic” or “heterocycle” may also include oxosubstituted partially saturated heterocyclic rings which contain a substituted ring nitrogen, such as N-alkyl pyridones. For example, the term “heterocyclyl”, “heterocyclic” or“heterocycle” may include groups such
[0043] The term “bridged ring systems” includes ring systems in which two rings share more than two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992. Suitably the bridge is formed between two non-adjacent carbon or nitrogen atoms in the ring system. The bridge connecting the bridgehead atoms may be a bond or comprise one or more atoms. Examples of bridged heterocyclyl ring systems include, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane, and quinuclidine.
[0044] The term “spiro bi-cyclic ring systems” includes ring systems in which two ring systems share one common spiro carbon atom, i.e., the heterocyclic ring is linked to a further carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 3,8-diaza-bicyclo[3.2.1 ]octane, 2,5-diaza-bicyclo[2.2.1 ]heptane, 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 6-oxa-2-azaspiro[3.4]octane, 2,7-diaza-spiro[4.4]nonane, 2-azaspiro[3.5]nonane, 2-oxa-7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.
[0045] The term “aromatic” when applied to a substituent as a whole includes a single ring or polycyclic ring system with 4n + 2 electrons in a conjugated n system within the ring or ring system where all atoms contributing to the conjugated n system are in the same plane.
[0046] The term “aryl” includes an aromatic hydrocarbon ring system. The ring system has 4n +2 electrons in a conjugated n system within a ring where all atoms contributing to the conjugated n system are in the same plane. An aryl may be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. For example, the “aryl” may be a C6-12 aryl, suitably phenyl or naphthyl. The aryl system itself may be substituted with other groups. The term “aryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring.
[0047] The term “heteroaryl” includes an aromatic mono- or bicyclic ring incorporating one or more (for example 1-4, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The ring or ring system has 4n + 2 electrons in a conjugated n system where all atoms contributing to the conjugated n system are in the same plane.
[0048] Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring, for example a bicyclic structure formed from fused five and six membered rings or two fused six membered rings, also referred to as a “fused bicyclic heteroaryl”. Bicyclic heteroaryl groups can be vicinally fused, i.e., where the rings are linked to each other through two adjacent carbon and / or nitrogen atoms. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically, the heteroaryl ring will contain up to 4, for example up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general, the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
[0049] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 1 H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1 -b]thiazolyl, imidazo[1,2-b][1,2,4]triazinyl, imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, imidazo[1,2-b]pyridazine, triazolo[1,5-a]pyridine, [1,2,3]triazolo[1,5-a]pyridine,. Examples of heteroaryl groups comprising at least one nitrogen in a ring position include pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl and pteridinyl.
[0050] Examples of five-membered heteroaryl groups include but are not limited to pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.
[0051] Examples of six-membered heteroaryl groups include but are not limited to pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.
[0052] The term “heteroaryl” may also include groups that are tautomers of hydroxy substituted heteroaryl groups, such as pyridones. For example, the term “heteroaryl” mayinclude groups such
[0053] The term “oxo,” or “=O” as used herein, means an oxygen that is double bonded to a carbon atom.
[0054] The term "optionally substituted" includes either groups, structures, or molecules that are substituted and those that are not substituted.
[0055] Where optional substituents are chosen from “one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specifiedgroups or the substituents being chosen from two or more of the specified groups, which may be the same or different. For example, “one or more optional substituents” may refer to 1 or 2 or 3 substituents (e.g. 1 substituent or 2 substituents).
[0056] Where a moiety is substituted, it may be substituted at any point on the moiety where chemically possible and consistent with atomic valency requirements. The moiety may be substituted by one or more substituents, e.g., 1, 2, 3 or 4 substituents; optionally there are 1 or 2 substituents on a group. Where there are two or more substituents, the substituents may be the same or different.
[0057] Substituents are only present at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without undue effort which substitutions are chemically possible and which are not.
[0058] Ortho, meta and para substitution arewell understood terms in the art. Forthe absence of doubt, “ortho” substitution is a substitution pattern where adjacent carbons possess a substituent, whether a simple group, for example the fluoro group in the example below, or other portions of the molecule, as indicated by the bond ending in “jJ'r
[0059] “Meta” substitution is a substitution pattern where two substituents are on carbons one carbon removed from each other, i.e., with a single carbon atom between the substituted carbons. In other words, there is a substituent on the second atom away from the atom with another substituent. For example, the groups below are meta substituted:
[0060] “Para” substitution is a substitution pattern where two substituents are on carbons two carbons removed from each other, i.e., with two carbon atoms between the substituted carbons. In other words, there is a substituent on the third atom away from the atom with another substituent. For example, the groups below are para substituted:
[0061] Where Z1, Z2, Z3, Z4, Z5, or Z6, are carbon, said carbon may be substituted by R2to give -CHR2- or =CR2- at any position other than the point at which thegroup is attached to the remainder of the compound. Similarly, where Z1, Z2, Z3, Z4, Z5, orZ6, arecarbon, said carbon may be the point at which thegroup is attached to the remainder of the compound, e.g.:
[0063] The term “nitrogen”, when used in relation to Z1, Z2, Z3, Z4, Z5, Z6, A1, A2, A3, B1, and B2, refers to nitrogen in it’s standard valency, unless otherwise stated. For example, “nitrogen” may referto -N=, -NH-, or-NR-, e.g. -NR2- or-NR5-.
[0064] For the avoidance of doubt, where a nitrogen atom is depicted by ‘N’ in a heteroaryl group, said nitrogen may be -N=, -NH-, or-NR-. For example, the group
[0065] In Ring B, a nitrogen atom depicted by ‘N’ in a heteroaryl group may be -N= or -NR-. For example, the group
[0066] The term “carbon”, when used in relation to Z2, Z3, Z5, Z6, A1, A2, A3, B1, and B2, refers to carbon in it’s standard valency, unless otherwise stated. For example, “carbon” may refer to -CH=, -CH2-, -CR=, -C(H)R-, or-CR2-, e.g. -C(R5)2-, or -CR6=, where chemically possible.
[0067] Reference to a -NRR’ group forming a 4 to 6 membered heterocycloalkyl refers to R and R’ together with the nitrogen atom to which they are attached forming a 4 to 6 membered heterocycloalkyl group. For example, a -NR2aR2b, -NR4aR4b, -NR5aR5b, -NR6aR6b, -NR7aR7b, and -NR8aR8bgroup may form:
[0068] A bond terminating in a “jJ'r”, i.e.”, represents that the bond is connected to another atom that is not shown in the structure. A bond terminating inside a cyclic structure and not terminating at an atom of the ring structure represents that the bond may be connectedto any of the atoms in the ring structure where allowed by valency, unless stated otherwise herein.
[0069] The various functional groups and substituents making up the compounds of the present invention are typically chosen such that the molecular weight of the compound does not exceed 1000. More usually, the molecular weight of the compound will be less than 750, for example less than 700, or less than 650, or less than 600, or less than 550.
[0070] Suitable or preferred features of any compounds of the present invention may also be suitable features of any other aspect.
[0071] The invention contemplates pharmaceutically acceptable salts of the compounds of the invention. These may include the acid addition and base salts of the compounds. These may be acid addition and base salts of the compounds.
[0072] Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulfate / sulfate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 1,5-naphthalenedisulfonate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.
[0073] Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts. For a review on suitable salts, see " Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
[0074] Pharmaceutically acceptable salts of compounds of the invention may be prepared by for example, one or more of the following methods:(i) by reacting the compound of the invention with the desired acid or base;(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of the invention or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or(iii) by converting one salt of the compound of the invention to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
[0075] These methods are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
[0076] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric centre, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterised by the absolute configuration of its asymmetric centre and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextro rotatory or levorotatory (i.e., as (+)or (-)-isomers respectively). Achiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”. Where a compound of the invention has two or more stereo centres any combination of (R) and (S) stereoisomers is contemplated. The combination of (R) and (S) stereoisomers may result in a diastereomeric mixture or a single diastereoisomer. The compounds of the invention may be present as a single stereoisomer or may be mixtures of stereoisomers, for example racemic mixtures and other enantiomeric mixtures, and diasteroemeric mixtures. Where the mixture is a mixture of enantiomers the enantiomeric excess may be any of those disclosed above. Where the compound is a single stereoisomer, the compounds may still contain other diasteroisomers or enantiomers as impurities. Hence a single stereoisomer does not necessarily have an enantiomeric excess (e.e.) or diastereomeric excess (d.e.) of 100% but could have an e.e. or d.e. of about at least 85%, for example at least 90%, at least 95%, at least 99%, or at least 99.9%.
[0077] The compounds of this invention may possess one or more asymmetric centres; such compounds can therefore be produced as individual (R) or (S)stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or namingof a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (see discussion in Chapter 4 of“Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. Some of the compounds of the invention may have geometric isomeric centres (E and Z isomers). It is to be understood that the present invention encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof
[0078] Z / E (e.g., cis / trans) isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
[0079] Conventional techniques for the preparation / isolation of individual enantiomers when necessary include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). Thus, chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and for specific examples, 0 to 5% by volume of an alkylamine e.g., 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
[0080] Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and / or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
[0081] When any racemate crystallises, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
[0082] While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate. Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, “Stereochemistry of Organic Compounds” by E. L. Eliel and S. H. Wilen (Wiley, 1994).
[0083] Compounds and salts described in this specification may be isotopically-labelled (or “radio-labelled”). Accordingly, one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of radionuclides that may be incorporated include2H (also written as “D” for deuterium),3H (also written as “T” for tritium),11C,13C,14C,15O,17O,18O,13N,15N,18F,36Cl,123I,25I,32P,35S and the like. The radionuclide that is used will depend on the specific application of that radio-labelled derivative. For example, for in vitro competition assays,3H or14C are often useful. For radio-imaging applications,11C or18F are often useful. In some embodiments, the radionuclide is3H. In some embodiments, the radionuclide is14C. In some embodiments, the radionuclide is11C. And in some embodiments, the radionuclide is18F.
[0084] Isotopically-labelled compounds can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.
[0085] The selective replacement of hydrogen with deuterium in a compound may modulate the metabolism of the compound, the PK / PD properties of the compound and / or the toxicity of the compound. For example, deuteration may increase the half-life or reduce the clearance of the compound in vivo. Deuteration may also inhibit the formation of toxic metabolites, thereby improving safety and tolerability. It is to be understood that the invention encompasses deuterated derivatives of compounds of formula (I). As used herein, the term deuterated derivative refers to compounds of the invention where in a particular position at least one hydrogen atom is replaced by deuterium. Accordingly, in a compound of the invention one or more hydrogen atom is optionally replaced by deuterium. For example, one or more hydrogen atoms in a Ci.4-alkyl group may be replaced by deuterium to form a deuterated Ci.4-alkyl group. By way of example, if any of R1a, R1b, Raor Rbis H, the invention also encompasses R1a, R1b, Raor Rbbeing D. By way of further example, if any of R1a, R1b, R2, R3, R4, R5, R6, R7, R8, R2a, R4a, R5a, R6a, R7a, R8a, R2b, R4b, R5b, R6b, R7b, and R8bare methyl, the invention also encompasses -CD3, -CHD2and -CH2D.
[0086] Certain compounds of the invention may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.
[0087] It is also to be understood that certain compounds of the invention may exhibit polymorphism, and that the invention encompasses all such forms.
[0088] Compounds of the invention may exist in a number of different tautomeric forms and references to compounds of the invention include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by compounds of the invention. Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the followingtautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.keto enol enolate
[0089] The / n vivo effects of a compound of the invention may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the invention.
[0090] It is further to be understood that a suitable pharmaceutically-acceptable pro-drug of a compound of the formula (I) also forms an aspect of the present invention. Accordingly, the compounds of the invention encompass pro-drug forms of the compounds and the compounds of the invention may be administered in the form of a pro-drug (i.e., a compound that is broken down in the human or animal body to release a compound of the invention). A pro-drug may be used to alter the physical properties and / or the pharmacokinetic properties of a compound of the invention. A pro-drug can beformed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached. Examples of pro-drugs include in v / vo-cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the invention and in v / vo-cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the invention.
[0091] Accordingly, the present invention includes those compounds of the invention as defined herein when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the formula (I) that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the formula (I) may be a synthetically-produced compound ora metabolically-produced compound.
[0092] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.
[0093] Various forms of pro-drug have been described, for example in the following documents:- a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);c) ATextbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991);d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);e) H. Bundgaard, etal., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, etal., Chem. Pharm. Bull., 32, 692 (1984);g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A. C. S. Symposium Series, Volume 14; andh) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.
[0094] A suitable pharmaceutically-acceptable pro-drug of a compound of the formula (I) that possesses a carboxy group is, for example, an in v / vo-cleavable ester thereof. An in vivo-cleavable ester of a compound of the invention containing a carboxy group is, for example, a pharmaceutically-acceptable esterwhich is cleaved in the human oranimal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include Ci_6alkyl esters such as methyl, ethyl and tert-butyl, Ci_6alkoxymethyl esters such as methoxymethyl esters, Ci.6alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3- p hthalidyl esters, C3. s cycloalkylcarbonyloxy- Ci_6alkyl esters such as cyclopentylcarbonyloxymethyl and 1 -cyclohexylcarbonyloxyethyl esters, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and Ci-6alkoxycarbonyloxy- Ci_6alkyl esters such as methoxycarbo nyloxymethyl and 1 -methoxycarbonyloxyethyl esters.
[0095] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention that possesses a hydroxy group is, for example, an in v / vo-cleavable ester or ether thereof. An in v / vo-cleavable ester or ether of a compound of the invention containing a hydroxy group is, for example, a pharmaceutically-acceptable ester or ether which is cleaved in the human or animal bodyto produce the parent hydroxy compound. Suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include CMO alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, CMO alkoxycarbonyl groups such as ethoxycarbonyl, A / , A / -(Ci.6alkyl)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, A / -alkylaminomethyl, A / , A / -dialkylaminomethyl, morpholinomethyl, piperazin-1 -ylmethyl and 4-(Ci.4alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically-acceptable ether forming groups for a hydroxy group include 0-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.
[0096] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention that possesses a carboxy group is, for example, an in v / vo-cleavable amide thereof, for example an amide formed with an amine such as ammonia, a Ci.4alkylamine such as methylamine, a (Ci.4alkyl)2amine such as dimethylamine, A / -ethyl-A / -methylamine or diethylamine, a Ci.4alkoxy- C2.4alkylamine such as 2-methoxyethylamine, a phenyl-Ci.4alkylamine such as benzylamine and amino acids such as glycine oran esterthereof.
[0097] A suitable pharmaceutically-acceptable pro-drug of a compound of the invention that possesses an amino group is, for example, an in v / vo-cleavable amide or carbamate derivative thereof. Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with C O alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, A / -alkylaminomethyl, N, N-dialkylaminomethyl, morpholinomethyl, piperazin-1 -ylmethyl and 4-(Ci.4alkyl)piperazin-1 -ylmethyl. Suitable pharmaceutically-acceptable carbamates from an amino group include, for example acyloxyalkoxycarbonyl and benzyloxycarbonyl groups.
[0098] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses theplural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
[0099] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and / or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
[0100] The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.COMPOUNDS
[0101] According to the first aspect, there is provided a compound of formula (I), as described herein.
[0102] In an embodiment, the compound of formula (I) is a compound of formula (II), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5; andR2, R5, B1, B2, Z1, Z2, Z3, Ring B and Ring C are as defined for formula (I).
[0103] In an embodiment, the compound of formula (I) is a compound of formula (III), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5; andR2, R5, B1, B2, Z1, Z2, Z3, Ring B and Ring C are as defined for formula (I).
[0104] In an embodiment, the compound of formula (I) is a compound of formula (IV), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2; andR2, A1, A2, A3, B1, B2, Z1, Z2, Z3, Ring A, Ring B and Ring C are as defined for formula (I).
[0105] In an embodiment, the compound of formula (I) is a compound of formula (V), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5; andR2, R5, B1, B2, Z1, Z2, Z3, Ring B and Ring C are as defined for formula (I).
[0106] In an embodiment, the compound of formula (I) is a compound of formula (VI), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6;Ring C is optionally substituted by one or more R8; andR2, R5, R6, R8, Z1, Z2, and Z3are as defined for formula (I).
[0107] In an embodiment, the compound of formula (I) is a compound of formula (VII), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6;Ring C is optionally substituted by one or more R8; andR2, R5, R6, R8, Z1, Z2, and Z3are as defined for formula (I).
[0108] In an embodiment, the compound of formula (I) is a compound of formula (VIII), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6;Ring C is optionally substituted by one or more R8; andR2, R5, R6, R8, Z1, Z2, and Z3are as defined for formula (I).
[0109] In an embodiment, the compound of formula (I) is a compound of formula (IX), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is a 5- to 6-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6;Ring C is optionally substituted by one or more R8; andR2, R5, R6, and R8are as defined for formula (I).
[0110] In certain embodiments compounds of the invention include, for example, compounds of formulae (I) to (IX), or a pharmaceutically acceptable salt and / or solvate thereof, wherein, unless otherwise stated, each group or variable has any of the meanings defined hereinbefore or in any of the following embodiments. These statements are independent and interchangeable. In other words, any of the features described in any one of the following embodiments may (where chemically allowable) be combined with the features described in one or more other embodiments below. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the statements below which describe a feature of that compound, expressed at any level of generality, may be combined so as to represent subject matter which is contemplated as forming part of the disclosure of this invention in this specification.
[0111] In an embodiment,, optionally substituted by one or more R2.
[0112] In an embodiment, Z1is NH or NR2.
[0113] In an embodiment, Z2is a bond. In an embodiment, Z2is a carbon. In an embodiment, Z2is a nitrogen. In an embodiment, Z2is an oxygen. In an embodiment, Z3is a bond. In an embodiment, Z3is a carbon. In an embodiment, Z3is a nitrogen. In an embodiment, Z3is an oxygen.
[0114] In an embodiment, Z2and Z3are independently selected from: carbon, nitrogen, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond, nitrogen, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond, carbon, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond, carbon and nitrogen. In an embodiment, Z2and Z3are independently selected from: a bond and carbon. In an embodiment, Z2and Z3are independently selected from: nitrogen, and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond and oxygen. In an embodiment, Z2and Z3are independently selected from: carbon and oxygen. In an embodiment, Z2and Z3are independently selected from: a bond and nitrogen. In an embodiment, Z2and Z3are independently selected from: carbon and nitrogen. In an embodiment, Z2and Z3is carbon. In an embodiment, Z2and Z3is nitrogen.
[0115] In an embodiment, Z1is nitrogen, Z2is a bond and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is a bond and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is a bond and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is a bond and Z3is oxygen.
[0116] In an embodiment, Z1is nitrogen, Z2is carbon and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is carbon and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is carbon and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is carbon and Z3is oxygen.
[0117] In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is nitrogen and Z3is oxygen.
[0118] In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is a bond. In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is carbon. In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is nitrogen. In an embodiment, Z1is nitrogen, Z2is oxygen and Z3is oxygen.
[0119] In an embodiment, Z1is NH. In an embodiment, Z1is N. In an embodiment, Z1is NR2.
[0120] In an embodiment, Z2is bonded to X1, such that
[0121] In an embodiment, Z3is bonded to X1, such that R1-X1- is
[0122] In an embodiment, R1is bonded to X1, such that R1-X1is
[0123] In an embodiment, R1is bonded to X1, such that
[0124] In an embodiment, Z1is bonded to X1, such that
[0125] In an embodiment,, optionally substituted by one or more R2.
[0126] In an embodiment, Z4is NH or NR2.
[0127] In an embodiment, Z5is a bond. In an embodiment, Z5is a carbon. In an embodiment, Z5is a nitrogen. In an embodiment, Z5is an oxygen. In an embodiment, Z6is a bond. In an embodiment, Z6is a carbon. In an embodiment, Z6is a nitrogen. In an embodiment, Z6is an oxygen.
[0128] In an embodiment, Z5and Z6are independently selected from: carbon, nitrogen, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond, nitrogen, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond, carbon, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond, carbon andnitrogen. In an embodiment, Z5and Z6are independently selected from: a bond and carbon. In an embodiment, Z5and Z6are independently selected from: nitrogen, and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond and oxygen. In an embodiment, Z5and Z6are independently selected from: carbon and oxygen. In an embodiment, Z5and Z6are independently selected from: a bond and nitrogen. In an embodiment, Z5and Z6are independently selected from: carbon and nitrogen. In an embodiment, Z5and Z6is a carbon. In an embodiment, Z5and Z6is a nitrogen.
[0129] In an embodiment, Z4is nitrogen, Z5is a bond and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is a bond and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is a bond and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is a bond and Z6is oxygen.
[0130] In an embodiment, Z4is nitrogen, Z5is carbon and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is carbon and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is carbon and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is carbon and Z6is oxygen.
[0131] In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is nitrogen and Z6is oxygen.
[0132] In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is a bond. In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is carbon. In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is nitrogen. In an embodiment, Z4is nitrogen, Z5is oxygen and Z6is oxygen.
[0133] In an embodiment, Z4is NH. In an embodiment, Z4is N. In an embodiment, Z4is NR2.
[0134] In an embodiment, Z5is bonded to X1, such that
[0135] In an embodiment, Z6is bonded to X1, such that
[0136] In an embodiment, R1is bonded to X1, such that
[0137] In an embodiment, R1is bonded to X1, such that
[0138] In an embodiment, Z4is bonded to X1, such that R1-X1- is
[0139] In an embodiment, R1is selected fromwherein said R1is optionally substituted with one or more R2.
[0140] In an embodiment, R1is selected fromoptionally substituted with one or more R2.
[0141] In an embodiment, R1is selected fromwherein said R1is optionally substituted with one or more R2.R1is optionally substituted with one or more R2.optionally substituted with one or more R2.substituted with one or more R2., wherein said R1is optionally substituted with one or more R2., wherein said R1is optionally substituted with one or more R2.
[0148] In an embodiment, R1is, wherein said R1is optionally substituted with one or more R2.
[0151] In an embodiment, R1is selected from
[0152] In an embodiment, R1is selected from,,
[0159] In an embodiment, R1is a 5 to 6-membered heteroaryl. In an embodiment, R1is a 5-membered heteroaryl. In an embodiment, R1is a 6-membered heteroaryl. Said R1is optionally substituted with one or more R2.
[0160] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from: furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole (e.g.1,2,4-triazole or 1,2,3-triazole), pyridine, pyridazine, pyrimidine, pyrazine and triazine (e.g. 1,2,4-triazine or 1,3,5-triazine), wherein said R1is optionally substituted with one or more R2.
[0161] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:substituted with one or more R2.
[0162] In an embodiment, R1is a 5-membered heteroaryl selected from: furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole and triazole (e.g. 1,2,4-triazole or 1,2,3-triazole) wherein said R1is optionally substituted with one or more R2.
[0163] In an embodiment, R1is a 5-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.
[0164] In an embodiment, R1is a 5-membered heteroaryl selected from:; wherein said R1is optionally substituted with one or more R2.
[0165] In an embodiment, R1is a 6-membered heteroaryl selected from: pyridine, pyridazine, pyrimidine, pyrazine and triazine (e.g. 1,2,4-triazine or 1,3,5-triazine), wherein said R1is optionally substituted with one or more R2.
[0166] In an embodiment, R1is a 6-membered heteroaryl selected from:wherein said R1is optionally substituted with one or more R2.
[0167] In an embodiment, R1is a 6-membered heteroaryl selected from:
[0168] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.
[0169] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:is optionally substituted with one or more R2.
[0170] In an embodiment, R1is a 5-membered heteroaryl selected from:wherein said R1is optionally substituted with one or more R2.
[0171] In an embodiment, R1is a 5-membered heteroaryl selected from:wherein said R1is optionally substituted with one or more R2.
[0172] In an embodiment, R1, wherein said R1is optionally substituted with one or more R2.
[0173] In an embodiment, R1is a 6-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.
[0174] In an embodiment, R1is a 5-membered heteroaryl selected from:
[0175] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:R1is optionally substituted with one or more R2.
[0177] In an embodiment, R1is a 5-membered heteroaryl selected from:
[0178] In an embodiment, R1is a 5-membered heteroaryl selected from:wherein said R1is optionally substituted with one or more R2.
[0179] In an embodiment, R1is a 6-membered heteroaryl with the formula
[0180] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from: pyrazole, imidazole, isoxazole, 1,2,4-triazole, pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.HN-N
[0181] In an embodiment, R1is a 5- or 6-membered heteroaryl selected from:wherein said R1is optionally substituted with one or more R2.
[0182] In an embodiment, R1is a 5-membered heteroaryl selected from: pyrazole, imidazole, isoxazole and 1,2,4-triazole, wherein said R1is optionally substituted with one or more R2.H
[0183] In an embodiment, R1is a 5-membered heteroaryl selected from:HN-Nand, wherein said R1is optionally substituted with one or more R2.
[0184] In an embodiment, R1is a 6-membered heteroaryl selected from: pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.
[0185] In an embodiment, R1is a 6-membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.
[0186] In an embodiment, R1is selected frommembered heteroaryl selected from: pyrazole, imidazole, isoxazole, 1,2,4-triazole, pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.membered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.
[0188] In an embodiment, R1is selected frommembered heteroaryl selected from: pyrazole, imidazole, isoxazole and 1,2,4-triazole wherein said R1is optionally substituted with one or more R2.optionally substituted with one or more R2.
[0190] In an embodiment, R1is selected frommembered heteroaryl selected from: pyridine, pyridazine and pyrazine, wherein said R1is optionally substituted with one or more R2.
[0191] In an embodiment, R1is selected frommembered heteroaryl selected from:, wherein said R1is optionally substituted with one or more R2.said R1is optionally substituted with one or more R2.optionally substituted with one or more R2.0O=sHN
[0194] In an embodiment, R1is, wherein said R1is optionally substituted with one or more R2., wherein said R1is optionally substituted with one or more R2.
[0196] In an embodiment, R1is substituted by one R2group.
[0197] In an embodiment, R1is substituted by two independently selected R2groups.
[0198] In an embodiment, R1is substituted by three independently selected R2groups.
[0199] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci-6haloalkyl, C2-6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.
[0200] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci_6alkyl, C2.6alkenyl or C2.6alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0201] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci-6haloalkyl, -S(O)xR2a, -C(O)R2a.
[0202] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci_6haloalkyl, -S(O)xR2a, -C(O)R2a, optionally wherein the Ci_6alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0203] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl.
[0204] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl, optionally wherein the Ci.6alkyl group can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0205] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.
[0206] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci_3haloalkyl, -S(O)xR2a, -C(O)R2a, optionally wherein the Ci_3alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0207] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-3alkyl, C1-3haloalkyl, -S(O)xR2a, -C(O)R2a.
[0208] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci_3haloalkyl, optionally wherein the Ci_3alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0209] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci.3haloalkyl.
[0210] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_6alkyl, Ci-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci_6alkyl, C2.6alkenyl, C2.6alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0211] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_6alkyl, Ci-6haloalkyl, C2.6alkenyl, C2.6alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.
[0212] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.3alkyl, Ci.3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a, optionally wherein any of the Ci.3alkyl, C2.3alkenyl, C2.3alkynyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0213] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.3alkyl, Ci.3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a.
[0214] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl, optionally wherein the Ci.6alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0215] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-6alkyl, Ci.6haloalkyl.
[0216] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci.3haloalkyl, optionally wherein the Ci.3alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0217] In an embodiment, R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci-3alkyl, Ci.3haloalkyl.
[0218] In an embodiment, R2is selected from: deuterium, halo, Ci_6alkyl, and Ci_6haloalkyl, optionally wherein the Ci_6alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0219] In an embodiment, R2is selected from: deuterium, halo, Ci.6alkyl, and Ci.6haloalkyl.
[0220] In an embodiment, R2is selected from: deuterium, halo, Ci_3alkyl, and Ci_3haloalkyl, optionally wherein the Ci.3alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0221] In an embodiment, R2is selected from: deuterium, halo, Ci.3alkyl, and Ci.3haloalkyl.
[0222] In an embodiment, R2is selected from: halo, -ON, -NO2, -NR2aR2b, -OR2a, =O, Ci.6alkyl, Ci-6 haloalkyl, optionally wherein the Ci.6alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0223] In an embodiment, R2is selected from: halo, -ON, -NO2, -NR2aR2b, -OR2a, =O, Ci.6alkyl, Ci-6 haloalkyl.
[0224] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.3alkyl, Ci.3haloalkyl, optionally wherein the Ci.3alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0225] In an embodiment, R2is selected from: halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci.3alkyl, Ci.3haloalkyl.
[0226] In an embodiment, R2is selected from: halo, Ci.6alkyl, and Ci.6haloalkyl, optionally wherein the Ci.6alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0227] In an embodiment, R2is selected from: halo, Ci.6alkyl, and Ci.6haloalkyl.
[0228] In an embodiment, R2is selected from: halo, Ci.3alkyl, and Ci.3haloalkyl, optionally wherein the Ci.3alkyl groups can be substituted by one or more substituents independently at each occurrence selected from the group consisting of: deuterium and ORa, e.g. OH.
[0229] In an embodiment, R2is selected from: halo, Ci.3alkyl, and Ci.3haloalkyl.
[0230] In an embodiment, R2is Ci_6alkyl. In an embodiment, R2is C1.3 alkyl. In an embodiment, R2is preferably methyl. In an embodiment, R2is ethyl. In an embodiment, R2is propyl, e.g. isopropyl. Optionally, any of the alkyl groups mentioned herein can be substituted with deuterium or ORa, e.g. OH. Optionally, any of the alkyl groups mentioned herein can be substituted with ORa, e.g. OH. In an embodiment, R2is C1.3 alkyl-ORa, e.g. CH2-ORa, CH2CH2-ORaor CH2CH2CH2-ORa. In an embodiment, R2is CH2CH2-OH.
[0231] In an embodiment, R2is deuterium. In an embodiment, R2is halo (e.gfluoro, chloro, bromo or iodo). In an embodiment, R2is -CN. In an embodiment, R2is -NO2. In an embodiment, R2is -NR2aR2b. In an embodiment, R2is -OR2a(e.g. -OH). In an embodiment, R2is =O. In an embodiment, R2is Ci.6haloalkyl. In an embodiment, R2is Ci.3haloalkyl (e.g. CF3or CH2CHF2). In an embodiment, R2is C2.6alkenyl. In an embodiment, R2is C2.3alkenyl. In an embodiment, R2is C2-6alkynyl. In an embodiment, R2is C2.3alkynyl. In an embodiment, R2is C3.6cycloalkyl (e.g. cyclopropyl). In an embodiment, R2is 4- to 6-membered heterocycloalkyl. In an embodiment, R2is 4-membered heterocycloalkyl. In an embodiment, R2is 5-membered heterocycloalkyl. In an embodiment, R2is 6-membered heterocycloalkyl. In an embodiment, R2is S(O)xR2a. In an embodiment, R2is -C(O)R2a. In an embodiment, R2is -OC(O)R2a. In an embodiment, R2is -C(O)OR2a.
[0232] In an embodiment, R1is selected from:
[0236] In an embodiment, R1is a 5-membered heteroaryl selected from:
[0240] In an embodiment, R1is preferably selected from:and.,. In an embodiment, R1is. In anembodiment,
[0241] In an embodiment, R1is., In anembodiment, R1isan embodiment, R1is. In an embodiment, R1is. In an embodiment, R1is. In anembodiment,embodiment, R1i. In an embodiment, R1, In an embodiment, R1isIn an embodiment, R1i. In an embodiment, R1is. In an embodiment,R1is. In an embodiment, R1i. In an embodiment,. In an embodiment,embodiment,In anembodiment,embodiment,embodiment, R1, embodiment, R1an embodiment, R1is
[0242] In an embodiment, R1is -C(O)NR1aR1b.
[0243] In an embodiment, R1ais selected from: H, C1-3 alkyl, and C1-3 haloalkyl. In an embodiment, R1ais selected from: H and Ci-3alkyl. In an embodiment, R1ais selected from: H and methyl. In an embodiment, R1ais H. In an embodiment, R1ais methyl.
[0244] In an embodiment, R1ais a Ci_6alkyl. In an embodiment, R1ais a Ci.3alkyl. In an embodiment, the Ci.3alkyl is methyl, ethyl or propyl.
[0245] In an embodiment, R1ais a Ci_6haloalkyl. In an embodiment, R1ais a Ci.3haloalkyl (e.g. CF3).
[0246] In an embodiment, R1bis selected from: H, Ci-3alkyl, and Ci-3haloalkyl. In an embodiment, R1bis selected from: H and Ci-3alkyl. In an embodiment, R1bis selected from: H and methyl. In an embodiment, R1bis H. In an embodiment, R1bis methyl.
[0247] In an embodiment, R1bis a Ci_6alkyl. In an embodiment, R1bis a Ci.3alkyl. In an embodiment, the Ci.3alkyl is methyl, ethyl or propyl.
[0248] In an embodiment, R1bis a Ci_6haloalkyl. In an embodiment, R1bis a Ci.3haloalkyl (e.g. CF3).
[0249] In an embodiment, R1aand R1bare each Ci-3alkyl. In an embodiment, R1ais H and R1bis Ci-3alkyl.
[0250] In an embodiment, R1is -C(O)NH2. In an embodiment, R1is -C(O)NHMe. In an embodiment, R1is -C(O)NMe2.
[0251] In an embodiment, X1is selected from: a bond, -O- and -NR3-. In an embodiment, X1is selected from: a bond, -O- and -S(O)X-. In an embodiment, X1is selected from: a bond, -NR3-and -S(O)X-. In an embodiment, X1is selected from: -O-, -NR3- and -S(O)X-.
[0252] In an embodiment, X1is selected from: a bond and -O-. In an embodiment, X1is selected from: a bond and -NR3. In an embodiment, X1is selected from: a bond and -S(O)X-. In an embodiment, X1is selected from: -O- and -NR3-. In an embodiment, X1is selected from: -O-and -S(O)X-. In an embodiment, X1is selected from: -NR3- and -S(O)X-.
[0253] In an embodiment, X1is a bond. In an embodiment, X1is -O-. In an embodiment, X1is -NR3-. In an embodiment, X1is -S(O)X-, wherein x is 0, e.g., X1is -S-. In an embodiment, X1is -S(O)X-, wherein x is 1, e.g., X1is -S(O)-. In an embodiment, X1is -S(O)X-, wherein x is 2, e.g., X1is -S(O)2-.
[0254] Preferably, X1is a bond.
[0255] In an embodiment, wherein R3is independently selected from: deuterium, H, C1-3 alkyl, C1-3 haloalkyl, C3-4cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-Ci-3alkyl.
[0256] In an embodiment, wherein R3is independently selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-Ci-3alkyl.
[0257] In an embodiment, R3is deuterium. In an embodiment, R3is H. In an embodiment, R3is Ci-6alkyl. In an embodiment, R3is Ci-3alkyl. In an embodiment, the Ci-3alkyl is methyl, ethyl or propyl. In an embodiment, R3is Ci-6haloalkyl. In an embodiment, R3is C1-3haloalkyl (e.g. CF3). In an embodiment, R3is C3-6cycloalkyl. In an embodiment, R3is C3-4cycloalkyl. In an embodiment, R3is4-to6-membered heterocycloalkyl. In an embodiment, R3is-C(O)-Ci-6alkyl. In an embodiment, R3is -C(O)-Ci-3alkyl.
[0258] In an embodiment, L is -C(O)-. In an embodiment, L is a Ci-8alkylene, optionally substituted by one or more independently selected R4. In an embodiment, L is a Ci_5alkylene, optionally substituted by one or more independently selected R4. In an embodiment, L is a Ci-4alkylene, optionally substituted by one or more independently selected R4. Preferably, L is a Ci-3alkylene, optionally substituted by one or more independently selected R4. More preferably L is -CH2-, -CH2CH2- or -CH2CH2CH2-.
[0259] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-3alkyl, Ci_3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR4a, -C(O)R4a, -OC(O)R4a, -C(O)OR4a.
[0260] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-3alkyl, Ci.3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, -C(O)OR4a.
[0261] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-3alkyl, Ci.3haloalkyl.
[0262] In an embodiment, R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci-3alkyl.
[0263] In an embodiment, R4is selected from: deuterium, halo, -NR4aR4b, =O, Ci.3alkyl.
[0264] In an embodiment, R4is selected from: deuterium, -NR4aR4b, =O, Ci.3alkyl.
[0265] In an embodiment, R4is selected from: halo, -NR4aR4b, =O, Ci.3alkyl.
[0266] In an embodiment, R4is selected from: -NR4aR4b, =O, Ci.3alkyl.
[0267] In an embodiment, R4is deuterium. In an embodiment, R4is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R4is -CN. In an embodiment, R4is -NO2. In an embodiment, R4is -NR4aR4b. In an embodiment, R4is -OR4a(e.g. -OH). In an embodiment, R4is =O. In an embodiment, R4is Ci_6alkyl. In an embodiment, R4is Ci.3alkyl. In an embodiment the Ci.3alkyl is methyl, ethyl or propyl. In an embodiment, R4is Ci_6haloalkyl. In an embodiment, R4is Ci.3haloalkyl (e.g. CF3). In an embodiment, R4is C2.6alkenyl. In an embodiment, R4is C2.3alkenyl. In an embodiment, R4is C2.6alkynyl. In an embodiment, R4is C2.3alkynyl. In an embodiment, R4is C3-6cycloalkyl. In an embodiment, R4is C3.4cycloalkyl. In an embodiment, R4is 4- to 6-membered heterocycloalkyl. In an embodiment, R4is S(O)xR4awherein x is 0, e.g. R4is -S-. In an embodiment, R4is S(O)xR4awherein x is 1, e.g. R4is -S(O)-. In an embodiment, R4is S(O)xR4awherein x is 2, e.g. R4is -S(O)2-. In an embodiment, R4is -C(O)R4a. In an embodiment, R4is -OC(O)R4a. In an embodiment, R4is -C(O)OR4a.
[0268] In an embodiment, X2is: -O-. In an embodiment, X2is -S(O)X-, wherein x is 0, e.g. X2is -S-. In an embodiment, X2is -S(O)X-, wherein x is 1, e.g. X2is -S(O)-. In an embodiment, X2is -S(O)X-, wherein x is 2, e.g. X2is -S(O)2-.
[0269] Preferably, X2is -O-.
[0270] In an embodiment, the group of -X1-L-X2- is selected from: -Ci-8alkylene-O-, -Ci-8alkylene-S-, -Ci-8alkylene-S(O)-, and -Ci-8alkylene-S(O)2; optionally wherein said alkylene is substituted by one or more R4.
[0271] In an embodiment, the group of -X1-L-X2- is selected from: -Ci_5alkylene-O-, -Ci_5alkylene-S-, -Ci_5alkylene-S(O)-, and -Ci_5alkylene-S(O)2; optionally wherein said alkylene is substituted by one or more R4.
[0272] In an embodiment, the group of -X1-L-X2- is selected from: -C1-4 alkylene-O-, -Ci-4alkylene-S-, -Ci-4alkylene-S(O)-, and -Ci-4alkylene-S(O)2; optionally wherein said alkylene is substituted by one or more R4.
[0273] In an embodiment, the group of -X1-L-X2- is selected from: -Ci_3alkylene-O-, -C1.3 alkylene-S-, -Ci.3alkylene-S(O)-, and -Ci.3alkylene-S(O)2; optionally wherein said alkylene is substituted by one or more R4.
[0274] In an embodiment, the group of -X1-L-X2- is -Ci-8alkylene-O-. In an embodiment, the group of -X1-L-X2- is -Ci-5alkylene-O-. In an embodiment, the group of -X1-L-X2- is -Ci-4alkylene-O-. In an embodiment, preferably the group of -X1-L-X2- is -Ci.3alkylene-O-, e.g. Ci-alkylene-O-. In an embodiment, most preferably the group of -X1-L-X2- is -CH2-O-. In an embodiment, the group of -X1-L-X2- is -CH2CH2-O-.
[0275] In an embodiment, the group of -X1-L-X2- is -Ci-8alkylene-S-. In an embodiment, the group of -X1-L-X2- is -Ci-5alkylene-S-. In an embodiment, the group of -X1-L-X2- is -Ci-4alkylenes’. In an embodiment, the group of -X1-L-X2- is -Ci.3alkylene-S-. In an embodiment, the group of -X1-L-X2- is -CH2CH2-S-.
[0276] In an embodiment, the group of -X1-L-X2- is -Ci-8alkylene-S(O)2-. In an embodiment, the group of -X1-L-X2- is -Ci_5alkylene-S(O)2-. In an embodiment, the group of -X1-L-X2- is -Ci-4alkylene-S(O)2-. In an embodiment, the group of -X1-L-X2- is -Ci.3alkylene-S(O)2-. In an embodiment, the group of -X1-L-X2- is -CH2CH2-S(O)2-.
[0277] In an embodiment, A1is a bond. In an embodiment, A1is carbon. In an embodiment, A1is nitrogen.
[0278] In an embodiment, A2is a bond. In an embodiment, A2is carbon. In an embodiment, A2is nitrogen.
[0279] In an embodiment, A3is carbon. In an embodiment, A3is nitrogen.
[0280] In an embodiment, Ring A is a 5-membered heterocycloalkyl.
[0281] In an embodiment, Ring A is 5-membered heterocycloalkyl, wherein one of A1and A2is a bond and the other of A1and A2is carbon, and A3is carbon.
[0282] In an embodiment, Ring A is 5-membered heterocycloalkyl, wherein one of A1and A2is a bond and the other of A1and A2is carbon, and A3is nitrogen.
[0283] In an embodiment, Ring A is 5-membered heterocycloalkyl, wherein one of A1and A2is a bond and the other of A1and A2is nitrogen, and A3is carbon.
[0284] In an embodiment, Ring A is 5-membered heterocycloalkyl, wherein one of A1and A2is a bond and the other of A1and A2is nitrogen, and A3is nitrogen.
[0285] In paragraphs relating to Ring A, Ring A is optionally substituted by one or more R5.
[0286] In an embodiment, Ring A is a 5 membered heterocycloalkyl selected from:
[0287] In an embodiment, Ring A is a 5 membered heterocycloalkyl with the formula:This is the preferred embodiment when Ring A is a 5 membered heterocycloalkyl.
[0288] In an embodiment, Ring A is a 5 membered heterocycloalkyl with the formula:
[0289] In an embodiment, Ring A is a 5 membered heterocycloalkyl with the formula:
[0290] In an embodiment, Ring A is a 5 membered heterocycloalkyl with the formula:
[0291] In an embodiment, Ring A is a 5 membered heterocycloalkenyl.
[0292] In an embodiment, Ring A is 5-membered heterocycloalkenyl, wherein one of A1and A2is a bond and the other of A1and A2is carbon, and A3is carbon.
[0293] In an embodiment, Ring A is 5-membered heterocycloalkenyl, wherein one of A1and A2is a bond and the other of A1and A2is carbon, and A3is nitrogen.
[0294] In an embodiment, Ring A is 5-membered heterocycloalkenyl, wherein one of A1and A2is a bond and the other of A1and A2is nitrogen, and A3is carbon.
[0295] In an embodiment, Ring A is 5-membered heterocycloalkenyl, wherein one of A1and A2is a bond and the other of A1and A2is nitrogen, and A3is nitrogen.
[0296] In an embodiment, Ring A is a 5 membered heterocycloalkenyl selected from:
[0297] In an embodiment, Ring A is a 5 membered heterocycloalkenyl with the formula:
[0298] In an embodiment, Ring A is a 5 membered heterocycloalkenyl with the formula:
[0299] In an embodiment, Ring A is a 5 membered heterocycloalkenyl with the formula:
[0300] In an embodiment, Ring A is a 5 membered heterocycloalkenyl with the formula:
[0301] In an embodiment, Ring A is a 6-membered heterocycloalkyl.
[0302] In an embodiment, Ring A is 6-membered heterocycloalkyl, wherein A1, A2, and A3are each carbon.
[0303] In an embodiment, Ring A is 6-membered heterocycloalkyl, wherein one of A1and A2is nitrogen and the other of A1and A2is carbon, and A3is carbon.
[0304] In an embodiment, Ring A is 6-membered heterocycloalkyl, wherein each of A1and A2is nitrogen, and A3is carbon.
[0305] In an embodiment, Ring A is 6-membered heterocycloalkyl, wherein each of A1and A2is carbon and A3is nitrogen.
[0306] In an embodiment, Ring A is 6-membered heterocycloalkyl, wherein one of A1and A2is nitrogen and the other of A1and A2is carbon, and A3is nitrogen.
[0307] In an embodiment, Ring A is 6-membered heterocycloalkyl, wherein A1, A2, and A3are each nitrogen.
[0308] In an embodiment, Ring A is a 6 membered heterocycloalkyl selected from:
[0309] In an embodiment, Ring A is a 6 membered heterocycloalkyl with the formula:. This is the preferred embodiment when Ring A is a 6 membered heterocycloalkyl.
[0310] In an embodiment, Ring A is a 6 membered heterocycloalkyl selected from:
[0312] In an embodiment, Ring A is a 6 membered heterocycloalkyl with the formula:
[0314] In an embodiment, Ring A is a 6 membered heterocycloalkyl with the formula:
[0315] In an embodiment, Ring A is a 6-membered heterocycloalkenyl.
[0316] In an embodiment, Ring A is 6-membered heterocycloalkenyl, wherein A1, A2, and A3are each carbon.
[0317] In an embodiment, Ring A is 6-membered heterocycloalkenyl, wherein one of A1and A2is nitrogen and the other of A1and A2is carbon, and A3is carbon.
[0318] In an embodiment, Ring A is 6-membered heterocycloalkenyl, wherein each of A1and A2is nitrogen, and A3is carbon.
[0319] In an embodiment, Ring A is 6-membered heterocycloalkenyl, wherein each of A1and A2is carbon and A3is nitrogen.
[0320] In an embodiment, Ring A is 6-membered heterocycloalkenyl, wherein one of A1and A2is nitrogen and the other of A1and A2is carbon, and A3is nitrogen.
[0321] In an embodiment, Ring A is 6-membered heterocycloalkenyl, wherein A1, A2, and A3are each nitrogen.
[0322] In an embodiment, Ring A is a 6 membered heterocycloalkenyl selected from:
[0323] In an embodiment, Ring A is a 6 membered heterocycloalkenyl with the formula:
[0325] In an embodiment, Ring A is a 6 membered heterocycloalkenyl with the formula:
[0326] In an embodiment, Ring A is a 6 membered heterocycloalkenyl with the formula:
[0328] In an embodiment, Ring A is a 6 membered heterocycloalkenyl with the formula:
[0329] In an embodiment, Ring A is P wherein n is an integer selected from 0 to 6. In an embodiment n is 0. In an embodiment n is 1. In an embodiment n is 2. In an embodiment n is 3.
[0330] Preferably, Ring
[0331] In an embodiment, Ring A is optionally substituted by one R5. In an embodiment, Ring A is optionally substituted by two independently selected R5groups. In an embodiment, RingA is optionally substituted by three independently selected R5groups.
[0332] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, Ci-3alkyl, Ci_3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a.
[0333] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, Ci-6alkyl, Ci_6haloalkyl, -C(O)R5a. In an embodiment, R5is selected from: halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, Ci.3alkyl, Ci-3haloalkyl, -C(O)R5a.
[0334] In an embodiment, R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, Ci-6alkyl. In an embodiment, R5is selected from: halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, Ci.3alkyl.
[0335] In an embodiment, R5is deuterium. In an embodiment, R5is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R5is -CN. In an embodiment, R5is -NO2. In an embodiment,R5is -NR5aR5b. In an embodiment, R5is -OR5a(e.g. -OH). In an embodiment, R5is =O. In an embodiment, R5is Ci.6alkyl. In an embodiment, R5is Ci_3alkyl. In an embodiment the Ci_3alkyl is methyl, ethyl or propyl. In an embodiment, R5is Ci.6haloalkyl. In an embodiment, R5is Ci.3haloalkyl (e.g. CF3). In an embodiment, R5is C2.6alkenyl. In an embodiment, R5is C2.3alkenyl. In an embodiment, R5is C2.6alkynyl. In an embodiment, R5is C2.3alkynyl. In an embodiment, R5is C3-6cycloalkyl. In an embodiment, R5is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R5is 4- to 6-membered heterocycloalkyl. In an embodiment, R5is 4-membered heterocycloalkyl. In an embodiment, R5is 5-membered heterocycloalkyl. In an embodiment, R5is 6-membered heterocycloalkyl. In an embodiment, R5is -S(O)xR5a. In an embodiment, R5is -C(O)R5a. In an embodiment, R5is -OC(O)R5a. In an embodiment, R5is -C(O)OR5a.
[0336] In an embodiment, R5is fluoro. In an embodiment, R5is chloro. In an embodiment, R5is bromo. In an embodiment, R5is iodo. In an embodiment, R5is methyl. In an embodiment, R5is ethyl. In an embodiment, R5is propyl.
[0337] In an embodiment, Ring B is 5-membered heteroaryl.
[0338] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond and B2is carbon.
[0339] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is a bond and B2is nitrogen.
[0340] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is carbon and B2is a bond.
[0341] In an embodiment, Ring B is a 5-membered heteroaryl, wherein B1is nitrogen and B2is a bond.
[0342] In an embodiment, the groupoptionally substituted by one or more R6on Ring B.
[0343] In an embodiment, the groupoptionally substituted by one or more R6on Ring B.
[0344] In an embodiment, the group:
[0345] In an embodiment, the group:
[0346] In an embodiment, the group:
[0347] In an embodiment, the group:
[0348] In an embodiment, the group:, optionally substituted by one or more R6on Ring B.
[0349] In an embodiment, the group:
[0350] In an embodiment, the group:, optionally substituted by one or more R6on Ring B.
[0351] In an embodiment, the group:
[0352] In an embodiment, the groupis selected from:
[0353] In an embodiment, the group
[0354] In an embodiment, the group
[0355] In an embodiment, the group:
[0356] In an embodiment, Ring B is 6-membered heteroaryl.
[0357] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is carbon and B2is carbon.
[0358] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is carbon and B2is nitrogen.
[0359] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is nitrogen and B2is carbon.
[0360] In an embodiment, Ring B is a 6-membered heteroaryl, wherein B1is nitrogen and B2is nitrogen.
[0361] In an embodiment, the groupis selected from:optionally substituted by one or more R6on Ring B.
[0362] In an embodiment, the group:.wherein said 6-membered heteroaryl is optionally substituted by one or more R6.
[0363] Preferably, the group:
[0364] In an embodiment, the group:
[0365] In an embodiment, the group:, optionally substituted by one or more R6on Ring B.
[0366] In an embodiment, the groupis selected from:
[0367] In an embodiment, the group:
[0368] In paragraphs relating to Ring B, Ring B is optionally substituted by one or more R6.
[0369] In an embodiment, Ring B is optionally substituted by one R6. In an embodiment, Ring B is optionally substituted by two independently selected R6groups. In an embodiment, Ring B is optionally substituted by three independently selected R6groups.
[0370] In an embodiment, where B1and / or B2is / are nitrogen, said nitrogen is selected from -N= or-NR6-.
[0371] In an embodiment, R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.
[0372] In an embodiment, R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 4-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a;
[0373] In an embodiment, R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6 cycloalkyl, 4-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.
[0374] In an embodiment, R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.
[0375] In an embodiment, R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.
[0376] In an embodiment, R6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1-3alkyl, C1-3haloalkyl, C2-3alkenyl, C2-3alkynyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a.
[0377] In an embodiment, R6is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R6is -CN. In an embodiment, R6is -NO2. In an embodiment, R6is -NR6aR6b. In an embodiment, R6is -OR6a(e.g. -OH). In an embodiment, R6is =O. In an embodiment, R6is C1-6alkyl. In an embodiment, R6is C1-3alkyl. In an embodiment the C1-3alkyl is methyl, ethyl or propyl. In an embodiment, R6is C1-6haloalkyl (e.g. CF3). In an embodiment, R6is C1-3haloalkyl (e.g. CF3). In an embodiment, R6is C2-6alkenyl. In an embodiment, R6is C2-3alkenyl. In an embodiment, R6is C2-6alkynyl. In an embodiment, R6is C2-3alkynyl. In an embodiment, R6is C3-6cycloalkyl. In an embodiment, R6is C3-4cycloalkyl (e.g. cyclopropyl). In an embodiment, R6is 4- to 6-membered heterocycloalkyl. In an embodiment, R6is 4-membered heterocycloalkyl. In an embodiment, R6is 5-membered heterocycloalkyl. In an embodiment, R6is 6-membered heterocycloalkyl. In an embodiment, R6is -S(O)xR6a. In an embodiment, R6is -C(O)R6a. In an embodiment, R6is -OC(O)R6a. In an embodiment, R6is -C(O)OR6a.
[0378] In an embodiment, R6is selected from: deuterium, halo, -OR6a, C1-6alkyl. In an embodiment, R6is selected from: deuterium, halo, -OR6a, C1-3alkyl. In an embodiment, R6is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R6is fluoro. In an embodiment, R6is chloro. In an embodiment, R6is deuterium. In an embodiment, R6is OH. In an embodiment, R6is methyl. In an embodiment, R6is ethyl.
[0379] In an embodiment, the groupis selected from:
[0380] In an embodiment, the group:
[0381] In an embodiment, the group
[0382] In an embodiment, the groupis selected from:
[0383] In an embodiment, the group
[0384] In an embodiment, the groupis selected from:
[0385] In an embodiment, the group:
[0386] In an embodiment, the group:
[0387] In an embodiment, the group:
[0388] In an embodiment, the group:
[0389] In an embodiment, the group:
[0390] In an embodiment, the group:
[0391] In an embodiment Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R7or R8groups.
[0392] In an embodiment, Ring C is a 4-membered cycloalkyl optionally substituted by one or more R7. In an embodiment, RingC is a 5-membered cycloalkyl optionally substituted by one or more R7. In an embodiment, RingC is a 6-membered cycloalkyl optionally substituted by one or more R7. In an embodiment, RingC is a 7-membered cycloalkyl optionally substituted by one or more R7.
[0393] In an embodiment, RingC is a 5-membered cycloalkenyl optionally substituted byone or more R7. In an embodiment, Ring C is a 6-membered cycloalkenyl optionally substituted by one or more R7. In an embodiment, RingC is a 7-membered cycloalkenyl optionally substituted byone or more R7.
[0394] In an embodiment, Ring C is a 4-membered heterocycloalkyl optionally substituted by one or more R7. In an embodiment, Ring C is a 5-membered heterocycloalkyl optionally substituted by one or more R7. In an embodiment, Ring C is a 6-membered heterocycloalkyl optionally substituted by one or more R7. In an embodiment, Ring C is a 7-membered heterocycloalkyl optionally substituted by one or more R7.
[0395] In an embodiment, RingC is a 5-membered heterocycloalkenyl optionally substituted byone or more R7. In an embodiment, Ring C is a 6-membered heterocycloalkenyl optionally substituted by one or more R7. In an embodiment, Ring C is a 7-membered heterocycloalkenyl optionally substituted by one or more R7.
[0396] Preferably, Ring C is a phenyl which is optionally substituted by one or more R8. In an embodiment, Ring C is a 5-membered heteroaryl optionally substituted by one or more R8. In an embodiment, RingC is a 6-membered heteroaryl optionally substituted byone or more R8.
[0397] In an embodiment, Ring C is substituted by one R7. In an embodiment, Ring C is substituted by two independently selected R7groups. In an embodiment, Ring C is substituted by three independently selected R7groups. In an embodiment, Ring C is substituted by fourindependently selected R7groups. In an embodiment, Ring C is substituted by five independently selected R7groups.
[0398] In an embodiment, Ring C is substituted by one R8. In an embodiment, Ring C is substituted by two independently selected R8groups. In an embodiment, RingC is substituted by three independently selected R8groups. In an embodiment, Ring C is substituted by four independently selected R8groups.
[0399] In an embodiment, the groupwherein each Y is independently selected from: oxygen, nitrogen or sulphur and wherein said Ring C is optionally substituted by one or more R7or R8.
[0400] In an embodiment, the groupwherein each Y is independently selected from: oxygen, nitrogen or sulphur and wherein said Ring C is optionally substituted by one or more R7or R8.
[0401] In an embodiment, the groupwherein said Ring C is optionally substituted by one or more R7or R8.
[0402] In an embodiment, the group
[0403] In an embodiment, the group
[0405] In an embodiment, the group10
[0406] In an embodiment, the group
[0409] In paragraphs relating to Ring C, Ring C is optionally substituted by one or more R7.
[0410] In an embodiment, Ring C is optionally substituted by one R7. In an embodiment, Ring C is optionally substituted by two independently selected R7groups. In an embodiment, Ring C is optionally substituted by three independently selected R7groups.
[0411] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci-3alkyl, Ci_3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.
[0412] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci-3alkyl, Ci.3haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.
[0413] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.
[0414] In an embodiment, R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci.3alkyl, Ci.3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a.
[0415] In an embodiment, R7is deuterium. In an embodiment, R7is halo (e.gfluoro, chloro, bromo or iodo). In an embodiment, R7is -CN. In an embodiment, R7is -NO2. In an embodiment, R7is -NR7aR7b. In an embodiment, R7is -OR7a(e.g. -OH). In an embodiment, R7is =O. In an embodiment, R7is Ci_6alkyl. In an embodiment, R7is Ci.3alkyl. In an embodiment the Ci.3alkyl is methyl, ethyl or propyl. In an embodiment, R7is Ci_6haloalkyl. In an embodiment, R7is Ci.3haloalkyl (e.g. CF3). In an embodiment, R7is C2.6alkenyl. In an embodiment, R7is C2.3alkenyl. In an embodiment, R7is C2.6alkynyl. In an embodiment, R7is C2.3alkynyl. In an embodiment, R7is C3-6cycloalkyl. In an embodiment, R7is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R7is 4- to 6-membered heterocycloalkyl. In an embodiment, R7is 4-membered heterocycloalkyl. In an embodiment, R7is 5-membered heterocycloalkyl. In an embodiment, R7is 6-membered heterocycloalkyl. In an embodiment, R7is -S(O)xR7a. In an embodiment, R7is -C(O)R7a. In an embodiment, R7is -OC(O)R7a. In an embodiment, R7is -C(O)OR7a.
[0416] In paragraphs relating to Ring C, Ring C is optionally substituted by one or more R8.
[0417] In an embodiment, Ring C is optionally substituted by one R8. In an embodiment, Ring C is optionally substituted by two independently selected R8groups. In an embodiment, Ring C is optionally substituted by three independently selected R8groups.
[0418] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, Ci-3alkyl, C1-3 haloalkyl, C2.3alkenyl, C2.3alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.
[0419] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3 alkyl, C1-3 haloalkyl, C2.3alkenyl, C2.3alkynyl, C3.4cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.
[0420] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.
[0421] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3alkyl, C1-3haloalkyl, C2.3alkenyl, C2.3alkynyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a.
[0422] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-6alkyl, C1-6haloalkyl, C2-6alkenyl, C2-6alkynyl, -C(O)R8aand -C(O)OR8a.
[0423] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, Ci-6alkyl, Ci-6haloalkyl and C2.6alkynyl.
[0424] In an embodiment, R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, C1-3alkyl, C1-3haloalkyl and C2.3alkynyl.
[0425] In an embodiment, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_6alkyl and Ci-6haloalkyl.
[0426] In an embodiment, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_6alkyl.
[0427] Preferably, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_3alkyl and Ci_3haloalkyl.
[0428] Preferably, R8is selected from: deuterium, halo, -CN, -OR8a, Ci_3alkyl.
[0429] In an embodiment, R8is deuterium. In an embodiment, R8is halo. In an embodiment, R8is halo (e.g. fluoro, chloro, bromo or iodo). In an embodiment, R8is -CN. In an embodiment, R8is -NO2. In an embodiment, R8is -NR8aR8b. In an embodiment, R8is -OR8a(e.g. -OH). In an embodiment, R8is Ci_6alkyl. In an embodiment, R8is Ci_3alkyl. In an embodiment the Ci_3alkyl is methyl, ethyl or propyl. In an embodiment, R8is Ci_6haloalkyl. In an embodiment, R8is Ci_3haloalkyl (e.g. CF3). In an embodiment, R8is C2.6alkenyl. In an embodiment, R8is C2.3alkenyl. In an embodiment, R8is C2.6alkynyl. In an embodiment, R8is C2.3alkynyl. In an embodiment, R8is C3-6cycloalkyl. In an embodiment, R8is C3.4cycloalkyl (e.g. cyclopropyl). In an embodiment, R8is 4- to 6-membered heterocycloalkyl. In an embodiment, R8is 4-membered heterocycloalkyl. In an embodiment, R8is 5-membered heterocycloalkyl. In an embodiment,R8is 6-membered heterocycloalkyl. In an embodiment, R8is -S(O)xR8a. In an embodiment, R8is -C(O)R8a. In an embodiment, R8is -OC(O)R8a. In an embodiment, R8is -C(O)OR8a.
[0430] In an embodiment, R8is fluoro. In an embodiment, R8is chloro. In an embodiment, R8is bromo. In an embodiment, R8is iodo. In an embodiment, R8is OH. In an embodiment, R8is methyl. In an embodiment, R8is ethyl. In an embodiment, R8is propyl.
[0431] In an embodiment, where Ring C is a 4- to 7-membered heterocycloalkyl, 5- to 7-membered hetero cyclo alkenyl or 5- or 6-membered heteroaryl comprising one or more nitrogen, said nitrogen is selected from -N=, -NR7- or -NR8-.
[0432] In an embodiment, the group
[0433] In an embodiment, the groupis selected from:
[0434] In an embodiment, the group
[0435] In an embodiment, the group
[0438] In an embodiment, Ring B is a 5-membered heteroaryl wherein one of B1and B2is selected from: a bond, carbon and nitrogen, and the other of B1and B2is selected from: carbon and nitrogen wherein Ring B is optionally substituted by one or more R6, and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R7or R8groups.
[0439] In an embodiment, Ring B is a 6-membered heteroaryl wherein B1and B2are selected from: carbon and nitrogen, wherein Ring B is optionally substituted by one or more R6, and Ring C is selected from: 5- to 6-membered cycloalkyl, 5- to 6-membered cycloalkenyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R7or R8groups.
[0440] In an embodiment, Ring B is a 5-membered heteroaryl wherein one of B1and B2is selected from: a bond, carbon and nitrogen, and the other of B1and B2is selected from: carbon and nitrogen wherein Ring B is optionally substituted by one or more R6, and Ring C is selected from: phenyl and 6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.
[0441] In an embodiment, Ring B is a 6-membered heteroaryl wherein B1and B2are selected from: carbon and nitrogen, wherein Ring B is optionally substituted by one or more R6, and Ring C is selected from: phenyl and 6-membered heteroaryl, wherein Ring C is optionally substituted by one or more R8groups.
[0442] In an embodiment, Ring B is a 5-membered heteroaryl wherein one of B1and B2is selected from: a bond, carbon and nitrogen, and the other of B1and B2is selected from: carbon and nitrogen wherein Ring B is optionally substituted by one or more R6, and Ring C is selected from: 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl, and 5-membered heteroaryl, wherein Ring C is optionally substituted by one or more R7or R8groups.
[0443] In an embodiment, Ring B is a 6-membered heteroaryl wherein B1and B2are selected from: carbon and nitrogen, wherein Ring B is optionally substituted by one or more R6, and Ring C is selected from: 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl, and 5-membered heteroaryl, wherein Ring C is optionally substituted by one or more R7or R8groups.
[0444] In an embodiment, the groupis selected from:, optionally wherein Ring B is substituted by one or more R6and, further optionally wherein Ring C is substituted by one or more R7or R8.
[0445] In an embodiment, the groupis selected from:optionally wherein Ring B is substituted by one or more R6and, further optionally wherein Ring C is substituted by one or more R7or R8.
[0446] In an embodiment, the groupoptionally wherein Ring B is substituted by one or more R6and, further optionally wherein Ring C is substituted by one or more R7or R8.
[0447] In an embodiment, the group
[0448] In an embodiment, the groupis selected from:Ċ
[0449] In an embodiment, the groupis selected from:
[0450] In an embodiment, the group
[0451] In an embodiment, the groupis selected from:
[0455] In an embodiment, the group
[0456] In an embodiment, the group
[0457] In an embodiment, the group
[0458] In an embodiment, the group
[0459] In an embodiment, the group
[0460] In an embodiment, the group
[0461] In an embodiment, the group
[0462] In an embodiment, the group
[0463] In an embodiment, the group
[0465] In an embodiment, where B1and / or B2is / are nitrogen, said nitrogen is selected from -N= or -NR6-; and where Ring C is a 4- to 7-membered heterocycloalkyl, 5- to 7-membered hetero cyclo alkenyl or 5- or 6-membered heteroaryl comprising one or more nitrogen, said nitrogen is selected from -N=, -NR7- or -NR8-.
[0466] In an embodiment, R2a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: H, C1-3 alkyl, C1-3 haloalkyl, C3-6cycloalkyl, and 4- to 6-membered heterocycloalkyl.
[0467] In an embodiment, R2a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: H, C1-3alkyl, C1-3haloalkyl.
[0468] In an embodiment, R2a, R4a, R5a, R6a, R7a, and R8aare each independently H.
[0469] In an embodiment, R2a, R4a, R5a, R6a, R7a, and R8aare each independently C1-3alkyl (e.g. methyl, ethyl or propyl).
[0470] In an embodiment, R2a, R4a, R5a, R6a, R7a, and R8aare each independently C1-3haloalkyl (e.g. CF3).
[0471] In an embodiment, R2ais selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R4ais selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R5ais selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R6ais selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R7ais selected from: H,C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R8ais selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl.
[0472] In an embodiment, R2b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: H, C1-3alkyl, C1-3haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-C1-3alkyl.
[0473] In an embodiment, R2b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: H, C1-3 alkyl, C1-3 haloalkyl.
[0474] In an embodiment, R2b, R4b, R5b, R6b, R7b, and R8bare each independently H.
[0475] In an embodiment, R2b, R4b, R5b, R6b, R7b, and R8bare each independently C1-3 alkyl (e.g. methyl, ethyl or propyl).
[0476] In an embodiment, R2b, R4b, R5b, R6b, R7b, and R8bare each independently C1-3 haloalkyl (e.g. CF3).
[0477] In an embodiment, R2bis selected from: H, C1-3 alkyl, C1-3 haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R4bis selected from: H, C1-3 alkyl, C1-3 haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R5bis selected from: H, C1-3 alkyl, C1-3 haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R6bis selected from: H, C1-3 alkyl, C1-3 haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R7bis selected from: H, C1-3alkyl, C1-3haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl. In an embodiment, R8bis selected from: H, C1-3 alkyl, C1-3 haloalkyl, C3-4cycloalkyl, and 4- to 6-membered heterocycloalkyl.
[0478] In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 4-membered hetero cyclo a Iky I ring. In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R2aand R2b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.
[0479] In an embodiment, at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 4-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R4aand R4b,together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R4aand R4b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.
[0480] In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 4-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R5aand R5b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.
[0481] In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 4-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R6aand R6b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.
[0482] In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, form a 4-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, may form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R7aand R7b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.
[0483] In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 4-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 5-membered heterocycloalkyl ring. In an embodiment, at each occurrence, R8aand R8b, together with the nitrogen atom to which they are attached, form a 6-membered heterocycloalkyl ring.
[0484] In an embodiment, each x is independently 0. In an embodiment, each x is independently 1. In an embodiment, each x is independently 2.
[0485] In an embodiment, any of the aforementioned alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, phenyl, or heteroaryl groups is optionally substituted, where chemically possible, by one or more substituents independently at each occurrence selected from the group consisting of: C1-3 alkyl, C1.3 alkyl-ORa, deuterium, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra.
[0486] In an embodiment, Rais independently at each occurrence H. In an embodiment, Rais independently at each occurrence Ci-4alkyl (e.g. methyl, ethyl, propyl or butyl).
[0487] In an embodiment, Rais independently at each occurrence H. In an embodiment, Rais independently at each occurrence Ci-3alkyl (e.g. methyl, ethyl or propyl).
[0488] In an embodiment, Rbis independently at each occurrence H. In an embodiment, Rbis independently at each occurrence Ci-4alkyl. In an embodiment the Ci-4alkyl is methyl, ethyl, propyl or butyl. In an embodiment, Rbis independently at each occurrence C(O)-Ci-4alkyl. In an embodiment, Rbis independently at each occurrence S(O)2-Ci-4alkyl.
[0489] In an embodiment, Rbis independently at each occurrence H. In an embodiment, Rbis independently at each occurrence Ci-3alkyl. In an embodiment the Ci.3alkyl is methyl, ethyl or propyl. In an embodiment, Rbis independently at each occurrence C(O)-Ci-3alkyl. In an embodiment, Rbis independently at each occurrence S(O)2-Ci-3alkyl.
[0490] The compound according to formula (I) per se is not a compound selected from:
[0491] In an embodiment, the compound of the invention is a compound selected from Compound List 1, or a pharmaceutically salt and / or solvate thereof:Compound List 1
[0492] In another embodiment there is provided a compound selected from any one of the Examples herein, or a pharmaceutically acceptable salt and / or solvate thereof.
[0493] Particular compounds of the invention are those that have an EC50≤1000 nM, preferably ≤500 nM, still more preferably ≤100 nM, when measured in the TrkB dimerization protein complementation assay (PCA) described in the Examples.
[0494] Particular compounds of the invention are those that have an EC50of ≥10 μM, when measured in the 5-HT2aR p-arrestin recruitment assay described in the Examples.
[0495] Particular compounds of the invention are those that are able to induce dendritogenesis, when measured in the dendritogenesis assay described in the Examples.
[0496] Particular compounds of the invention are those that are able to induce dendritogenesis, when measured in the dendritogenesis assay described in the Examples, whilstalso havingan EC50≥10 μM, when measured in the 5-HT2aR β-arrestin recruitment assay described in the Examples. Such compounds exhibit the induction of neuronal plasticity without causing hallucinations mediated by the serotonin 2A (5-HT2A) receptor.
[0497] Suitably the compounds of the invention exhibit a favourable pharmacokinetic and / or pharmacodynamic profile, for example, one or more of favourable oral bioavailability, metabolic stability, plasma half-life.
[0498] Compounds of the invention may exhibit one or more beneficial properties. In embodiments, compounds of the invention demonstrate one or more beneficial Absorption, Distribution, Metabolism, and Excretion (ADME) property.PHARMACEUTICAL COMPOSITIONS
[0499] In accordance with another aspect, the present invention provides a pharmaceutical composition comprisinga compound of the invention, exceptthatthe compounds of List Aarenot excluded, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.
[0500] In an embodiment, there is provided a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.
[0501] Conventional procedures for the selection and preparation of suitable pharmaceutical compositions are described in, for example, " Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
[0502] The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for sublingual use, for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intraperitoneal dosing or as a suppository for rectal dosing).
[0503] The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and / or preservative agents.
[0504] An effective amount of a compound of the present invention for use in therapy of a condition is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of the condition orto slowthe progression of the condition.
[0505] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.1 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
[0506] The size of the dose for therapeutic or prophylactic purposes of a compound of the invention will naturally vary according to the nature and severity of the conditions, the age andsexof the animal or patient and the route of administration, according to well- known principles of medicine.
[0507] In usinga compound of the invention for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, a daily dose selected from 0.1 mg / kgto 100 mg / kg, 1 mg / kgto 75mg / kg, 1 mg / kgto50 mg / kg, 1 mg / kgto20 mg / kgor 5 mg / kgto 10 mg / kg body weight is received, given if required in divided doses. In general, lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous, subcutaneous, intramuscular or intraperitoneal administration, a dose in the range, for example, 0.1 mg / kg to 30 mg / kg body weight may be suitable. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg / kg to 25 mg / kg body weight may be suitable. When administered orally a total daily dose of a compound of the invention may be, for example, selected from: 1 mg to 1000 mg, 5 mg to 1000 mg, 10 mg to 750 mg or 25 mg to 500 mg. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of the invention. In a particular embodiment the compound of the invention is administered parenterally, for example by intravenous administration. In another particular embodiment the compound of the invention is administered orally.THERAPEUTIC USES AND APPLICATIONS
[0508] In this section describing therapeutic uses, applications and methods of treatment reference to “a compound of the invention” includes compounds according to formula (I), except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof. It may be that reference to “a compound of the invention” includes compounds according to formula (I), or a pharmaceutically acceptable salt and / or solvate thereof, i.e., where the compounds of List A are excluded.
[0509] In accordance with anotheraspect, the present invention provides a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament.
[0510] A further aspect of the invention provides a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the prevention ortreatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2).
[0511] Also provided is a method of preventing or treating a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) in a subject,the method comprising administering to the subject an effective amount of a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof.
[0512] In the following sections of the application reference is made to a compound of the invention, ora pharmaceutically acceptable salt and / or solvate thereof for use in the treatment of certain diseases or medical disorders. It is to be understood that any reference herein to a compound fora particular use is also intended to be a reference to (i) the use of the compound of the invention, or pharmaceutically acceptable salt and / or solvate thereof, in the manufacture of a medicament for the treatment of that disease or disorder; and (ii) a method for the treatment of the disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound of the invention, or pharmaceutically acceptable salt and / or solvate thereof.
[0513] In certain embodiments the disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2) is selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI).
[0514] In certain embodiments there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medicaldisorderselected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associated neurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI).
[0515] In certain embodiments there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder selected from: Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Bipolar Disorder (BD) and Traumatic Brain Injury (TBI).
[0516] In certain embodiments there is provided a compound of the invention, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a diseaseor medical disorder selected from: Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), and Traumatic Brain Injury (TBI).Combination Therapies
[0517] The compounds of the invention may be used alone to provide a therapeutic effect. The compounds of the invention may also be used in combination with one or more additional therapeutic agents.
[0518] Such combination treatment maybe achieved byway of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within a therapeutically effective dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
[0519] Herein, where the term “combination” is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention “combination” refers to simultaneous administration. In another aspect of the invention “combination” refers to separate administration. In a further aspect of the invention “combination” refers to sequential administration. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination.
[0520] In some embodiments in which a combination treatment is used, the amount of the compound of the invention and the amount of the other pharmaceutically active agent(s) are, when combined, therapeutically effective to treat a targeted disorder in the patient. In this context, the combined amounts are “therapeutically effective amount” if they are, when combined, sufficient to reduce or completely alleviate symptoms or other detrimental effects of the disorder; cure the disorder; reverse, completely stop, or slow the progress of the disorder; or reduce the risk of the disorder getting worse. Typically, such amounts may be determined by one skilled in the art by, for example, starting with the dosage range described in this specification for the compound of the invention and an approved or otherwise published dosage range(s) of the other pharmaceutically active compound(s).Biological Assays5-HT2aR p-arrestin recruitment assay
[0521] Compounds of the invention were tested for agonism of the 5-HT2aR using the PathHunter® 5-HT2aR p-arrestin recruitment assay. PathHunter® U2OS HTR2A p-arrestin cells (Cat # 93-0401 C3, DiscoverX, France) are cultured as per DiscoverXs’s protocol, with cellsseeded onto white 384-well plates at 5000 cells per well-1, and incubated overnight at 37°C, 5% CO2 in a humidified atmosphere.
[0522] On the day of assay compounds are added to the cells using a Multidrop™ Pico 8 to generate 10-point concentration response curves ranging between 10 pM and 5 pM, with a final [DMSO] concentration of 1% v / v. Cells are then incubated with compound for 2 hours at 37°C, 5% CO2 in a humidified atmosphere, followed by addition of the PathHunter® detection reagents (Cat #93-0001, DiscoverX, France) as per the suppliers protocol. Following a 1 hour incubation in the dark, at room temperature, luminescence is determined via use of a PHERastar FSX. All data is normalised to the activity observed for 10 pM LSD.Dendritogenesis assay
[0523] Dendritogenesis was measured in response to treatment with compounds of the invention in vitro. 384-well PhenoVue Plates (6057302, Rewity) were coated with poly-L-lysine hydrobromide (PLL; 10 pg / mL; P4707, SigmaAldrich) for 18 hours at 37°C. PLL-was aspirated followed by washing three times with Dulbecco’s phosphate-buffered saline (DPBS; D8537, SigmaAldrich) PLL-coated plates were left to dry in a laminar flow hood prior to use.
[0524] Cryovials of day-18 embryonic Fisher 334 rat cortical neurons (A1084001, ThermoFisher) were rapidly thawed in a 37°C water bath transferred into falcon tubes and diluted with pre-warmed Neurobasal™ Plus Medium (A3582901, ThermoFisher) supplemented with B-27™ plus (2% v / v; A3582801, ThermoFisher) and GlutaMAX™ (0.5 mM; 35050061, ThermoFisher) henceforth termed “neurobasal complete”). Addition of neurobasal complete to suspensions was performed in a dropwise manner. Neurons were seeded into PLL-coated plates at a density of 2000 cells per well-1, and incubated overnight (37°C, 5% CO2, humidified atmosphere). 24 hours post seeding a 50% media change was performed, followed by incubation (37°C, 5% CO2, humidified atmosphere) for 4 days.
[0525] Prior to compound addition neuronal cultures received a 50% media change with fresh, pre-warmed neurobasal complete. Compounds were dispensed onto neuronal cultures using the Multidrop™ Pico 8 digital dispenser (ThermoFisher) to final concentrations of 1, 0.1 or 0.01 pM, with a final [DMSO]concentration of 0.1 % v / v. 100 nM LSD (L001, SigmaAldrich) and 50 ng / ml BDNF (2837, Biotechne) were utilised as positive controls. For each tested condition 10-12 wells were treated. Following treatment, wells were immediately imaged (TO) in phase at 20X magnification using the Incucyte® S3 under incubating conditions (37°C, 5% CO2, humidified atmosphere), then again after 72 hours (T72). Neuronal neurite length and branch points were detected using the Incucyte® S3’s built-in neurotrack analysis software. Tonormalise dendritogenesis across wells, TO values from each analysis were subtracted from their respective T72 values. To account for plate-to-plate variation in culture responsiveness to LSD, analyses values were normalised to the observed activity of 100 nM LSD.TrkB dimerization protein complementation assay (PCA)
[0526] PCA was used as a protein- protein interaction assay in live N2a cells to evaluate TrkB dimerization in response to treatment with test compounds (1 nM - 1 pM). Split humanized Gaussia princeps luciferase (hGLuc) was cloned on the C-terminus of the reporter proteins TrkB. If the reporter proteins that carry complementary halves of the luciferase interact, the enzyme can refold in its functional conformation and, upon addition of its substrate, produce luminescence proportionally to the amount of reporter proteins interacting at a given time. N2a cells were seeded in 96-well plates with opaque walls and transparent bottom (PerkinElmer, ViewPlate96). Cells were transfected with Lipofectamine 2000 (Invitrogen, Ref: 11668019) according to manufacturer instructions 24 h post-plating with the PCA pair plasmids: phGLuc(1C)-TrkB(WT) and phGLuc(2C)-TrkB(WT) for the dimerization experiments. 48 h post transfection, cells were treated (40 min, 37 °C) in phenol-red free Dulbecco’s Modified Eagle Medium (PRF-free DMEM) without serum. PCA signal was detected with the substrate for the luciferase, coelenterazine (Coelenterazine Native: NanoLight Technology, Cat: #303-5; NanoFuel-Solvent: NanoLight Techonology, Cat: #399-10), which was injected into each well directly in the plate reader at a final concentration of 17.7 pM.Spinogenesis assay
[0527] Spinogenesis experiments were performed using cultures of hippocampal neurons from E18 rat embryos, derived from pregnant Wistar rats (strain HNL1 RccHan: WIST, Inotiv, Envigo). 50,000 cells per well were plated in 24 well plates containing 1.5H glass coverslips and grown for 21 days. Neuronal cultures were treated for 24 hours with DMSO (vehicle) ortest compounds (100 nM) with a final [DMSO] concentration of 0.1% v / v. After 24 hours, the coverslips were fixed with 4% PFAfor 20 minutes at room temperature, then washed with PBS. Afterwards they were incubated with blocking buffer (0.1% Triton X-100, 0.05% Tween-20, 10% normal donkey serum, 1% BSA and 0.1% gelatin in PBS) for 1 hour at room temperature and subsequently incubated overnightwith rabbit anti-MAP2 (Invitrogen, Ab32454; 1: 1000) primary antibody at 4 °C. Another series of PBS washes was performed, coverslips were incubated with donkey anti-rabbit antibody (Invitrogen, AF488; 1:1000) for 1 hour at room temperature. Another round of PBS washes was followed by incubation with Alexa Fluor 647-conjugated phalloidin (Invitrogen, A22287; 1:40) overnight at 4 °C. Then, coverslips were briefly washed in phosphate buffer (PB) and mountedon slides with Dako mounting medium (Agilent Technologies). Images were acquired with a Zeiss LSM 980 confocal with a PlanApochromat 63× / 1.4 NA objective. Six single plane pictures were taken of randomly selected neurons per coverslip. Finally, image analysis was conducted using ImageJ by experimenters blinded to treatment, with spine quantification performed on 15-pm-long dendrite segments.Synthesis
[0528] In the description of the synthetic methods described below and in the referenced synthetic methods that are used to prepare the staring materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be selected by a person skilled in the art.
[0529] It is understood by one skilled in the art of organic synthesis that the functionality presenton various portions of the molecule must be compatible with the reagents and reaction conditions utilised.
[0530] Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
[0531] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined below, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and howsuch protectinggroups may be put in place, and later removed.
[0532] For examples of protectinggroups see one of the many general texts on the subject, for example, ‘Protective Groups in Organic Synthesis’ by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemistas appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.
[0533] 1H-NMR: Spectra are obtained on a Jeol ECS 400 MHz spectrometer. Spectra are measured at 294K (unless otherwise stated) and chemical shifts (5-values) are reported in parts per million (ppm), referenced to either tetramethylsilane (0.0 ppm), DMSO-d6(2.50 ppm),CDCl3(7.26 ppm), acetonitrile-d3(1.94 ppm), CD2Cl2(5.32 ppm). Coupling constants (J) are reported in Hertz (Hz), spectra splitting pattern are designated as singlet (s), doublet (d), triplet (t), quadruplet (q), multiplet or more overlapping signals (m), broad signal (br); solvent is given in parentheses.1H-NMR integrations have been quantified when visible. When expected integrals are not observed, some proton signals are (partially) obscured by residual NMR solvent and / or water peak, and may be denoted as such, or assumed.EXAMPLESAbbreviations
[0534] The following abbreviations are used in the Examples and other parts of the description.Ac: acetateAq.: aqueousBSA: Bovine Serum AlbuminC: (degrees) CelsiusDa: DaltonDCE: dichloroethaneDCM: dichloromethaneDMF: A / , A / -DimethylformamideDMSO: Dimethylsulfoxidedppf: 1,1 ’-bis(diphenylphosphino)ferroceneESi: Electrospray ionizationeq. equivalentsEtOAc: ethyl acetateGM: general Methodh: hour(s)HPLC: high-performance liquid chromatographyIPA: Isopropyl alcoholmin / mins: minute(s)LCMS: liquid chromatography- mass spectrometryM: molarMeCN: acetonitrileMS: mass spectroscopyMs: methanesulfonylMW: microwaveNaHCO3: Sodium bicarbonateNa2SO4: Sodium sulfateNMR: nuclear magnetic resonancePBS: Phosphate Buffered SalinePDA: photo diode arrayPFA: paraformaldehydePrep: preparativequant.: quantitative (conversion)Rt: retention timeRT: room temperatureSat.: saturatedSCX: strong cation exchangeT: temperatureTFA: trifluoroacetic acidTH F: Tetra hyd rof u ra nTMS: trimethylsilylTs: 4-toluenesulfonylTsCl: Tosyl chlorideUPLC: ultra-performance liquid chromatographyAnalytical methods
[0535] Analysis of products and intermediates has been carried out using reversed phase analytical HPLC-MS using the parameters set out below.UPLC analytical methods were run on Waters Acquity UPLC with Waters QDA mass spectrometer.UPLC_PH9_MECN_QC_V1: Waters CSH C18 1.7 pm, 100 x 2.1 mm; A = pH 9 Aq 10mM ammonium bicarb water (adjusted with ammonia); B = MeCN; 50 °C; %B: 0.05 min 5%, 5 min95%, 6.6 min 5%, 0.35 mL / min. With PDA 210-400nm and MS detection 120-1000 Da, ESi + / -(Waters QDA LCMS)UPLC_PH7.4_MECN_QC_V1: Waters CSH C18 1.7 pm, 100 x 2.1 mm; A = pH 7.4 Aq 10mM ammonium bicarb water (adjusted with carbon dioxide); B = MeCN; 50 °C; %B: 0.05 min 5%, 5 min 95%, 6.6 min 5%, 0.35 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)UPLC_PH2_MECN_QC_V1: Waters CSH C181.7 pm, 100 x 2.1 mm; A = water + 0.1% formic acid; B = MeCN + 0.1% formic acid; 50 °C; %B: 0.05 min 5%, 5.00 min 95%, 6.60min 5% 0.35 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / -. (Waters QDA LCMS) UPLC_pH9_MECN_2.6MIN_V1: Waters BEH C18 1.7 pm, 50 x 2.1 mm; A = pH 9 Aq 10mM ammonium bicarb water (adjusted with ammonia); B = MeCN; 50 °C; %B: 0.05 min 5%, 1.60 min 95%, 2.25 min 5%, 0.6 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS)UPLC_PH2_MECN_2.6MIN_V1: Waters BEH C181.7 pm, 50 x 2.1 mm; A = water + 0.1 % formic acid; B = MeCN + 0.1% formic acid; 50 °C; %B: 0.05 min 5%, 1.60 min 95%, 2.25 min 5%, 0.6 mL / min. With PDA210-400nm and MS detection 120-1000 Da, ESi + / - (Waters QDA LCMS) General MethodsGeneral Method 1: SwAr
[0536] Amine (1 eq.), haloarene (1.2 - 2.0 eq.), and a base such as potassium phosphate (2 -5 eq.) were dissolved in a solvent such as water, DMSO or DMF (0.02 - 0.1 M) and stirred at 60 - 120 °C for 2 - 16 hours. The reaction mixture was diluted with water and ethyl acetate and the layers separated. The aqueous layer was extracted with ethyl acetate and the combined organic layers dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography or prep HPLC.General Method 2: O-Alkylation
[0537] Alcohol (1 eq.) was dissolved in tetra hydrofuran or DMF (0.02 - 0.1 M) and cooled to 0 °C. Sodium hydride (1.5 - 3.0 eq.) was added and the reaction mixture stirred for 10 minutes. Alkyl halide or pseudohalide (1.0-2.0 eq.) and potassium iodide (1.0-2.0 eq.) were added and the reaction mixture stirred at 25 -80 °C for 2 - 16 hours. The reaction mixture was diluted with water and dichloromethane or ethyl acetate and the layers separated. The aqueous layer was extracted with dichloromethane or ethyl acetate and the combined organic layers dried,filtered, concentrated in vacuo and the crude product purified by flash column chromatography or prep HPLC.General Method 3: Azine Reduction
[0538] Hypodiboric acid (7 eq.) was placed under a nitrogen atmosphere. A solution of the pyridine (1 eq.) in ethylene glycol (0.28 - 0.35 M) was added, the vessel evacuated and filled with nitrogen. Cyclooctadiene rhodium chloride dimer (0.2 eq.) was added and the reaction mixture stirred at 50 °C for 16 hours. For incomplete reactions, an additional amount of cyclooctadiene rhodium chloride dimer (0.2 eq.) and hypodiboric acid (7 eq.) was introduced followed by evacuation of the vessel, backfilled with nitrogen and the reaction mixture stirred at 50 °C for 3 - 16 hours. The mixture was filtered through celite and concentrated. The crude product was purified by dissolving the residue in methanol, passing the solution passed through an SCX2 cartridge, washing with methanol and eluting with methanolic ammonia (2M).General Method 4: Acid catalysed-deprotection
[0539] The protected amine, amide or carbamate was stirred in a solution of TFA in DCM (0.1 M - neat) at 25 - 150 °C for 1 - 16h. The reaction mixture was concentrated under reduced pressure to yield the crude material, which was optionally resuspended in DCM, washed with sodium bicarbonate (aq. sat.), brine (aq. sat.) and the organic layer concentrated under reduced pressure or purified by catch-release cartridge (Biotage SCX-2) washing with methanol and eluting with 0.7 - 7 M ammonia-methanol and concentrated under reduced pressure. The crude product was either used directly in the subsequent reaction or purified by flash column chromatography or preparative HPLC.General Method 5: N-alkylation of lactams
[0540] To a solution of the N / - / containing intermediate (0.1 - 0.5 M in THF or DMF) at -10 - 0 °C was added sodium hydride (60 % dispersion in oil, 3.0 -5.0 eq.) and the reaction mixture stirred at -10 - 0 °C for 10 - 30 min. lodomethane (3.0 - 5.0 eq.) was added and the reaction mixture stirred at -10- 25 °C for 1 - 16h.
[0541] The reaction mixture was cooled to -10 - 0 °C and quenched with ammonium chloride (aq., half sat.) and extracted with EtOAc. The combined organic extracts were washed with brine (aq. sat.) and then either dried (Na2SO4) and filtered or passed through a phase separator and concentrated in vacuo. The crude product was then either used directly in the next step without further purification or purified by flash column chromatography or preparative HPLC.General Method 6: Reduction of methyl esters to alcohols
[0542] To a stirred solution of the methyl ester (1 eq., 0.3 M in THF) at 0 °C was added dropwise, over 5-10 min. a 2 M solution of lithium borohydride in THF (2.4 eq.). Upon completion of the addition, the reaction mixture was allowed towarm to room temperature and stirred at room temperature for 1 - 16h.
[0543] The reaction mixture was quenched with ammonium chloride (aq., half sat.) and extracted with EtOAc. The combined organic extracts were washed with brine (aq. sat.), dried (Na2SO4), filtered and concentrated in vacuo. The crude product was then either used directly in the next step without further purification or purified by flash column chromatography.General Scheme 1: SNAr then alkylation
[0544] Example 1: (R)-2-(3-((1-Methyl-1H-pyrazol-3-yl)methoxy)piperidin-1-yl)quinoxaline
[0545] (R)-1-(Quinoxalin-2-yl)piperidin-3-ol
[0546] 2-Chloroquinoxaline (1.50 g, 9.11 mmol), (R)-3-hydroxypiperidine hydrochloride (1.13 g, 8.20 mmol) and potassium phosphate tribasic (5.80 g, 27.3 mmol) were dissolved in water (30 mL), and stirred at 100 °C for 16 hours. The reaction mixture was cooled, diluted with ethyl acetate (20 mL) and the layers separated. The aqueous layerwas extracted successively with EtOAc (2x 10 mL), and the combined organic layers washed with brine (sat. aq., 20 mL), dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography, eluting with 20-100 % ethyl acetate in isohexane to give (R)-1-(quinoxalin-2-yl)pi perid i n-3-ol (1.13 g, 54 %) as a yellow-green glassy solid.
[0547] 1H-NMR (400 MHz, DMSO-D6) 58.74 (t, J = 4.8 Hz, 1 H), 7.75-7.67 (m, 1 H), 7.55-7.48 (m, 2H), 7.35-7.24 (m, 1 H), 4.86 (d, J = 4.1 Hz, 1 H), 4.21 (dd, J = 12.8, 3.7 Hz, 1 H), 4.01 (dt, J =13.1, 3.7 Hz, 1H), 3.56 (qd, 7 = 8.1, 4.1 Hz, 1 H), 3.36-3.30 (m, 1 H), 3.18-3.08 (m, 1 H), 1.89-1.73 (m, 2H), 1.49-1.38 (m, 2H).
[0548] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.42 mins, m / z 230.0 [M+H]+
[0549] (R)-2-(3-((1-Methyl-1 H-pyrazol-3-yl)methoxy)piperidin-1-yl)quinoxaline
[0550] (R)-1-(Quinoxalin-2-yl)piperidin-3-ol (140 mg, 0.611 mmol) was dissolved in tetra hydrofuran (4.0 mL) and cooled to 0°C. Sodium hydride (60% dispersion in oil, 37 mg, 0.916 mmol) was added and the mixture stirred for 5 mins. 3-(Chloromethyl)-1-methyl-1 H-pyrazole (0.073 mL, 0.672 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. Potassium iodide (101 mg, 0.611 mmol) was added and the reaction mixture stirred at 60 °C for 5 hours. The reaction mixture was diluted with water and ethyl acetate, separated, and the aqueous layer extracted with ethyl acetate. The combined organic layers were dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography, eluting with 20-80 % ethyl acetate in isohexane. The semi-purified residue was further purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm) eluting with 30-70 % acetonitrile in pH9 ammonium bicarbonate to give (R)-2-(3-((1-methyl-1 H-pyrazol-3-yl)methoxy)piperidin-1-yl)quinoxaline (33.6mg, 17 %, Example 1) as a yellow oil.
[0551] 1H-NMR (400 MHz, DMSO-D6) 58.79 (t, J = 5.7 Hz, 1 H), 7.79 (dd, J = 8.2, 0.9 Hz, 1 H), 7.59-7.54 (m, 3H), 7.39-7.33 (m, 1 H), 6.11 (d, J = 2.3 Hz, 1 H), 4.47 (s, 2H), 4.16-4.10 (m, 1 H), 3.94-3.87 (m, 1 H), 3.77 (s, 3H), 3.62-3.51 (m, 3H), 1.97-1.92 (m, 1 H), 1.83-1.74 (m, 1 H), 1.65-1.56 (m, 1H), 1.53-1.43 (m, 1H).
[0552] UPLC_PH2_MECN_QC_V1: Rt 4.33 min, m / z 324.2 [M+H]+
[0553] UPLC_PH9_MECN_QC_V1: Rt4.45 min, m / z 324.2 [M+H]+The following compounds were made analogous to step 1 above, using General Method 1:
[0554] The following compounds were made analogous to step 2 above, using General Method 2:
[0555] Example 15: 1-methyl-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one
[0556] 1-Methyl-4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one
[0557] 3-Hydroxypyridine (101 mg, 1.06 mmol), (1-methyl-5-oxo-pyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (300 mg, 1.06 mmol) and potassium carbonate (439 mg, 3.18 mmol) were dissolved in N,N-dimethylformamide (4.0 mL) and the reaction mixture was stirred at 100 °C for 1 h. The reaction mixture was cooled, diluted with dichloromethane and filtered through celite. The solution was diluted with NaHCO3(aq. sat., 10 mL), and the layers separated. Theaqueous layer was concentrated in vacuo, resuspended in methanol, filtered through celite and concentrated in vacuo. The residue was purified by flash column chromatography, eluting with 0-10% methanol in dichloromethane to give 1-methyl-4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one (54.0 mg, 25 %) as a pale brown oil.
[0558] UPLC_PH2_MECN_2.6MIN_V1: Rt 1.13 mins, m / z 207.3 [M+H]+
[0559] 1 -Methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one
[0560] Hypodiboric acid (885 mg, 9.88 mmol) was placed in a flask under a nitrogen atmosphere before the addition of a solution of 1-methyl-4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one (291 mg, 1.41 mmol) in ethylene glycol (15 mL, 260 mmol). The vessel was evacuated and backfilled with nitrogen before the addition of cyclooctadiene rhodium chloride dimer (140 mg, 0.282 mmol). The vessel was evacuated and backfilled with nitrogen and then stirred at 50 °C for 16 hours. The reaction mixture was cooled, filtered through celite and cyclooctadiene rhodium chloride dimer (40 mg, 0.282 mmol) was added. The reaction vessel was evacuated and backfilled with nitrogen and the reaction mixture stirred at 50 °C for 3 hours. The reaction mixture was filtered through celite, concentrated in vacuo and redissolved in methanol. The solution was loaded onto an SCX2 cartridge, washed with methanol, and partially eluted with methanolic ammonia (0.7M), followed by eluting using methanolic ammonia (2M). The combined product-containing fractions were concentrated under reduced pressure to give 1-methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (80 mg, 27%) as a brown solid.
[0561] UPLC_PH2_MECN_2.6MIN_V1; Rt0.97 mins, m / z 213.4 [M+H]+
[0562] 1-Methyl-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one
[0563] 2-Chloroquinoxaline (62 mg, 0.38 mmol), 1-methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (80 mg, 0.38 mmol) and potassium phosphate tribasic (240 mg, 1.1 mmol) were suspended in water (8.0 mL) and the mixture stirred at 100 °C for 16 hours. A further aliquot of 2-chloroquinoxaline (62 mg, 0.38 mmol) was added and the reaction mixturestirred at 100 °C for a further 24 hours. The reaction mixture was cooled, diluted with ethyl acetate and the layers separated. The aqueous layer was extracted with ethyl acetate and the combined organic layers washed with brine (aq. sat.), dried, filtered and concentrated in vacuo. The crude product was purified by preparative HPLC: Waters XBridge (C18 5 µm OBD 19 x 250 mm), eluting with 20-60 % acetonitrile in ammonium bicarbonate (pH9). The productcontaining fractions were concentrated under reduced pressure and lyophilised from water:acetonitrile to give 1-methyl-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one (10 mg, 8 %) as a pale-yellow solid.
[0564] 1 H-NMR (400 MHz, CHLOROFORM-D) 58.58 (s, 1 H), 7.86 (d, J = 8.5 Hz, 1 H), 7.67-7.64 (m, 1 H), 7.56 (td, J = 7.6, 1.4 Hz, 1 H), 7.38 (td, J = 7.6, 1.2 Hz, 1 H), 4.15-4.10 (m, 1 H), 3.90-3.83 (m, 1 H), 3.65-3.26 (m, 6H), 3.07-3.02 (m, 1 H), 2.71 (s, 3H), 2.60-2.42 (m, 2H), 2.14 (dq, J = 16.8, 3.0 Hz, 1H), 1.99-1.89 (m, 1H), 1.71-1.61 (m, 3H).
[0565] UPLC_PH2_MECN_QC_V1: Rt 4.22 min, m / z 341.2 [M+H]+
[0566] UPLC_PH9_MECN_QC_V1: Rt 4.32 min, m / z 341.2 [M+H]+
[0567] Example 16: 4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one
[0568] 4-((Pyridin-3-yloxy)methyl)pyrrolidin-2-one
[0569] 3- Hydroxypyridine (134 mg, 1.40 mmol), 4-(bromomethyl)pyrrolidin-2-one (250 mg, 1.40 mmol) and potassium carbonate (582 mg, 4.21 mmol) were dissolved in N, N-dimethylformamide (7.0 mL) and the reaction mixture stirred at 100 °C for 16 hours. The reaction mixture was cooled, diluted with EtOAc (10 mL) and water (40 mL) and the layers separated. The organic layer was washed with water (2 x 10 mL), concentrated in vacuo, resuspended in methanol, dried, filtered, and concentrated in vacuo to give 4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one (270 mg) as a dark-brown oil which was used in the next step without further purification.
[0570] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.00 mins, m / z 193.0 [M+H]+
[0571] 4-((Piperidin-3-yloxy)methyl)pyrrolidin-2-one
[0572] Hypodiboric acid (881 mg, 9.83 mmol) and 4-(3-pyridyloxymethyl)pyrrolidin-2-one (270 mg, 1.40 mmol) were dissolved in ethylene Glycol (14 mL) under nitrogen before cyclooctadiene rhodium chloride dimer (139 mg, 0.281 mmol) was added and the reaction mixture stirred at 50 °C for 16 hours. The reaction mixture was filtered through celite before further hypodiboric acid (881 mg, 9.83 mmol) and cyclooctadiene rhodium chloride dimer (139 mg, 0.281 mmol) added under nitrogen and the reaction mixture stirred at 50 °C for 16 hours. The reaction mixture was filtered through celite, concentrated in vacuo and resuspended in water (20 mL) and ethyl acetate (20 mL). The layers were separated and the aqueous layer concentrated. The resultant residue was dissolved in methanol and purified by catch-release cartridge (Biotage SCX-2) washing with methanol and eluting with 2M ammonia in methanol to give 4-(3-piperidyloxymethyl)pyrrolidin-2-one (126 mg, 45 %) as a brown oil.
[0573] UPLC_PH9_MECN_2.6MIN_V1: Rt0.50 mins, m / z 199.0 [M+H]+
[0574] 4-(((1-(Quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one
[0575] Using GM1 with 4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one and 2-chloroquinoxaline, then purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm), eluting with 8-48 % acetonitrile in ammonium bicarbonate (pH9) to give 4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one (11.7mg, 6 %, Example 10) as a pale yellow solid.
[0576] 1H-NMR (400 MHz, DMSO-D6) δ 8.84 (s, 1H), 7.79 (d, J = 8.2 Hz, 1 H), 7.58-7.56 (m, 2H), 7.42 (s, 1H), 7.39-7.34 (m, 1H), 4.12 (dd, 7= 12.8, 2.3 Hz, 1H), 3.89 (qd,7 = 6.6, 3.8 Hz, 1H), 3.63-3.39 (m, 5H), 3.25-3.18 (m, 1H), 2.93-2.88 (m, 1H), 2.52 (s, 1 H), 2.18-2.07 (m, 1H), 1.95 (td,7 = 8.0, 3.8 Hz, 1 H), 1.88-1.75 (m, 2H), 1.64-1.45 (m, 2H).
[0577] UPLC_PH2_MECN_QC_V1: Rt 3.72 min, m / z 327.3 [M+H]+
[0578] UPLC_PH9_MECN_QC_V1: Rt 3.90 min, m / z 327.3 [M+H]+
[0579] Example 17: (R)-1-methyl-5-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyridin-2(1 H)-one
[0580] tert-Butyl (R)-3-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methoxy)piperidine-1-carboxylate
[0581] 5-(Hydroxymethyl)-1-methyl-1,2-dihydropyridin-2-one (110 mg, 0.79 mmol) was dissolved in dichloromethane (5 mL) and the solution cooled to 0 °C. A solution of thionyl bromide (0.09 mL, 1.18 mmol) in dichloromethane (5 mL) was added in one portion and the reaction allowed to warm to room temperature and stirred at room temperature for one hour. The reaction mixture was concentrated in vacuo. (R)-tert-Butyl 3-hydroxypiperidine-1-carboxylate (239 mg, 1.19 mmol) and potassium carbonate (219 mg, 1.58 mmol) in tetrahydrofuran (10 mL) was added and the mixture stirred at 80 °C for 16 hours. The reaction mixture was quenched with water, diluted with dichloromethane and the layers separated. The aqueous layer was extracted with dichloromethane and the combined organic layers dried, filtered and concentrated in vacuo. The residue was purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm) eluting with 20-60 % acetonitrile in aqueous ammonium carbonate (pH9) to give tert-butyl (3R)-3-[(1-methyl-6-oxo-3-pyridyl)methoxy]piperidine-1-carboxylate (80 mg, 31 %) as a colourless oil.
[0582] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.54 mins, m / z 323.3 [M+H]+
[0583] (R)-1-Methyl-5-((piperidin-3-yloxy)methyl)pyridin-2(1 H)-one
[0584] tert-Butyl (3R)-3-[(1-methyl-6-oxo-3-pyridyl)methoxy]piperidine-1 -carboxylate (80 mg, 0.248 mmol) was dissolved in trifluoroacetic acid (1.0 mL) and the reaction mixture stirred at room temperature for one hour. The reaction mixture was concentrated in vacuo, resuspended in sodium bicarbonate solution and dichloromethane, and the layers separated. The aqueous layer was extracted with dichloromethane and the combined organic layers dried, filtered, and concentrated in vacuo to give 1-methyl-5-[[(3R)-3-piperidyl]oxymethyl]pyridin-2-one (55 mg, 100 %) as an orange oil.
[0585] UPLC_PH9_MECN_2.6MIN_V1: Rt 0.86 mins, m / z 223.3 [M+H]+
[0586] (R)-1-Methyl-5-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyridin-2(1 H)-one
[0587] Using GM1 with (R)-1-methyl-5-((piperidin-3-yloxy)methyl)pyridin-2(1 H)-one and 2-chloroquinoxaline, then purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm), eluting with 20-60 % acetonitrile in ammonium bicarbonate (pH9) to give (R)-1-methyl-5-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyridin-2(1 H)-one (8.9 mg, 10 %, Example 11) as a yellow solid.
[0588] 1H-NMR (400 MHz, CHLOROFORM-D) 58.59 (s, 1 H), 7.87 (m, 1 H), 7.70 (m, 1 H), 7.56 (t, J = 7.6 Hz, 1 H), 7.40 (m, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.13 (s, 1 H), 6.50 (d, J = 9.2 Hz, 1 H), 4.36 (dd, J = 40.1, 11.2 Hz, 2H), 4.16 (d, J = 11.0 Hz, 1 H), 3.87 (q, J = 6.7 Hz, 1 H), 3.63 (d, J = 20.1 Hz, 3H), 3.38 (s, 3H), 2.05-1.94 (m, 2H), 1.79-1.69 (m, 1 H), 1.65-1.60 (m, 1 H).
[0589] UPLC_PH2_MECN_QC_V1: Rt4.12 min, m / z 351.2 [M+H]+
[0590] UPLC_PH7.4_MECN_QC_V1: Rt 4.02 min, m / z 351.3 [M+H]+
[0591] UPLC_PH9_MECN_QC_V1: Rt 4.57 min, m / z 351.3 [M+H]+
[0592] Example 18: 1-methyl-5-((((R)-1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)piperidin-2-one
[0593] Benzyl (R)-3-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methoxy)piperidine-1-carboxylate
[0594] 5-(Hydroxymethyl)-1-methyl-1,2-dihydropyridin-2-one (110 mg, 0.79 mmol) was dissolved in dichloromethane (5 mL) and the solution cooled to 0 °C. A solution of thionyl bromide (0.09 mL, 1.18 mmol) in dichloromethane (5 mL) was added in one portion and the reaction allowed to warm to room temperature and stirred at room temperature for one hour. The reaction mixture was concentrated in vacuo. (R)-Benzyl 3-hydroxypiperidine-1-carboxylate (279 mg, 1.19 mmol), and potassium carbonate (219 mg, 1.58 mmol) in tetrahydrofuran (10 mL) was added and the reaction mixture stirred at 80 °C for 16 hours. The reaction mixture was quenched with water, diluted with dichloromethane and the layers separated. The aqueous layer was extracted with dichloromethane and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm) eluting with 20-60 % acetonitrile in aqueous ammonium carbonate (pH9 to give benzyl (R)-3-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methoxy)piperidine-1-carboxylate (260 mg, 92 %) as a colourless oil.
[0595] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.57 mins, m / z 357.3 [M+H]+
[0596] 1-Methyl-5-((((R)-piperidin-3-yl)oxy)methyl)piperidin-2-one
[0597] Benzyl (3R)-3-[(1-methyl-6-oxo-3-pyridyl)methoxy]piperidine-1 -carboxylate (260 mg, 0.729 mmol) was dissolved in ethanol (25 mL) before palladium on carbon (78 mg, 0.729 mmol) was added. The solution was hydrogenated in the Parr Hydrogenator at room temperature at 32 psi of hydrogen. The reaction mixture was filtered through celite, concentrated in vacuo, and the crude product purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm) eluting with 20-60 % acetonitrile in aqueous ammonium carbonate (pH9) to give 70 mg of a semi-pure mixture as an orange oil which was used in the next step without further purification.
[0598] Benzyl (3R)-3-[(1-methyl-6-oxo-3-pyridyl)methoxy]piperidine-1-carboxylate (67 mg, 0.188 mmol) was dissolved in ethanol (5.0 mL). Palladium on carbon (20 mg, 0.188 mmol) was added and the flask evacuated, backfilled with hydrogen and stirred at room temperature for 4 hours. The reaction mixture was filtered through celite and concentrated in vacuo to give 1-methyl-5-((((R)-piperidin-3-yl)oxy)methyl)piperidin-2-one (42 mg, 99 %) as a white solid.
[0599] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.04 mins, m / z 227.3 [M+H]+
[0600] 1-Methyl-5-((((R)-1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)piperidin-2-one
[0601] 1-Methyl-5-[[(3R)-3-piperidyl]oxymethyl]piperidin-2-one (43 mg, 0.188 mmol), 2-chloroquinoxaline (62 mg, 0.376 mmol), and potassium phosphate tribasic (200 mg, 0.940 mmol) were dissolved in water (5.0 mL) and the reaction mixture stirred at 100 °C for 24 hours. The reaction mixture was concentrated in vacuo and resuspended in dimethyl sulfoxide (3.0 mL). The reaction mixture was stirred at 100 °C for 2 hours, concentrated in vacuo and the crude product purified by prep HPLC (Waters XBridge C185 pm OBD 19x 250 mm) eluting with 20-60 % acetonitrile in aqueous ammonium carbonate (pH9) to give 1-methyl-5-[[(3R)-1-quinoxalin-2-yl-3-piperidyl]oxymethyl]piperidin-2-one (17 mg, 26 %, Example 12) as a pale yellow solid.
[0602] 1H-NMR (400 MHz, DMSO-D6) 58.75 (s, 1 H), 7.75 (d, J = 7.8 Hz, 1 H), 7.56-7.50 (m, 2H), 7.34-7.30 (m, 1 H), 3.97 (d, J = 13.7 Hz, 1 H), 3.75-3.64 (m, 3H), 3.48-3.33 (m, 3H), 3.12-3.06 (m, 1 H), 2.90-2.81 (m, 1 H), 2.62 (s, 3H), 2.11-2.07 (m, 2H), 2.01-1.60 (m, 5H), 1.50-1.32 (m, 2H).
[0603] UPLC_PH2_MECN_QC_V1: Rt 4.78 min, m / z 355.3 [M+H]+
[0604] UPLC_PH7.4_MECN_QC_V1: Rt 4.23 min, m / z 355.3 [M+H]+
[0605] UPLC_PH9_MECN_QC_V1: Rt 4.33 min, m / z 355.3 [M+H]+General Scheme 2: Alkylation and Boc Deprotection Followed by SNAr
[0606] Example 19: (R)-3-(3-((1-Methyl-1H-pyrazol-3-yl)methoxy)piperidin-1-yl)benzo[e][1,2,4]triazine
[0607] (R)-3-((1-Methyl-1 H-pyrazol-3-yl)methoxy)piperidine
[0608] (R)-tert-Butyl 3-hydroxypiperidine-1 -carboxylate (500 mg, 2.48 mmol) was dissolved in tetrahydrofuran (10 mL). Sodium hydride (60% dispersion in oil, 199 mg, 4.97 mmol) was added and the mixture stirred at RT for one minute. 3-(Chloromethyl)-1-methyl-1H-pyrazole (487 mg, 3.73 mmol) and potassium Iodide (830 mg, 4.97 mmol) were added and the reaction mixture stirred at 80 °C for 2 hours. The reaction mixture was concentrated in vacuo and resuspended in dichloromethane (10 mL) before TFA (2.0 mL) was added. The reaction mixture was stirred at room temperature for one hour. The crude product was purified by catch-release cartridge (Biotage SCX-2) washing with methanol and eluting with 2M ammonia in methanol to give (R)-3-((1 -methyl-1 H-pyrazol-3-yl)methoxy)piperidine (474 mg, 98 %) as a yellow oil.
[0609] UPLC_PH9_MECN_2.6MIN_V1: Rt 0.92 mins, m / z 196.2 [M+H]+
[0610] (R)-3-(3-((1 -Methyl-1 H-pyrazol-3-yl)methoxy)piperidin-1 -yl)benzo[e][1,2,4]triazine
[0611] (R)-3-((1 -Methyl-1 H-pyrazol-3-yl)methoxy)piperidine (50 mg, 0.256 mmol), 3-chloro- 1,2,4-benzotriazine (42 mg, 0.256 mmol), and potassium phosphate tribasic (109 mg, 0.512 mmol) were dissolved in dimethyl sulfoxide (2.0 mL) and the reaction mixture stirred at 100 °C for one hour. The crude product was purified by prep HPLC (Waters XBridge C18 5 µm OBD 19 x 250 mm), eluting with 30 - 70 % acetonitrile in pH9 ammonium carbonate to give (R)-3-(3-((1-methyl-1H-pyrazol-3-yl)methoxy)piperidin-1-yl)benzo[e][1,2,4]triazine (60 mg, 72 %) as a yellow solid.
[0612] 1H-NMR (400 MHz, Chloroform-D) 58.19 (dd, 7 = 8.5, 1.1 Hz, 1 H), 7.69-7.65 (m, 1 H), 7.55 (d, J = 8.2 Hz, 1 H), 7.38-7.34 (m, 1 H), 7.27 (d, J = 2.3 Hz, 1 H), 6.22 (d, J = 2.3 Hz, 1 H), 4.70-4.60 (m, 3H), 4.45 (d, J = 17.4 Hz, 1 H), 3.86 (s, 3H), 3.67-3.56 (m, 3H), 2.14-2.09 (m, 1 H), 1.98- 1.90 (m, 1 H), 1.75-1.68 (m, 1 H), 1.63 (dd, J = 9.6, 3.7 Hz, 1 H).
[0613] UPLC_PH2_MECN_QC_V1: Rt 4.54 min, m / z 325.2 [M+H]+
[0614] UPLC_PH7_4_MECN_QC_V1: Rt 5.02 min, m / z 325.2 [M+H]+
[0615] UPLC_PH9_MECN_QC_V1: Rt 4.56 min, m / z 325.2 [M+H]+
[0616] The following compounds were made analogous to step 2 above, using General Method 1:
[0617] Example 24: (R)-3-(3-((1-Methyl-1 H-pyrazol-3-yl)methoxy)piperidin-1-yl)cinnoline
[0618] (R)-3-((1 -Methyl- 1 H-pyrazol-3-yl)methoxy)piperidine (42 mg, 0.215 mmol), 3-bromocinnoline (67 mg, 0.323 mmol), potassium tert-butoxide (48 mg, 0.430 mmol), and XantPhos Pd G3 (20 mg, 0.0215 mmol) were dissolved in 1,4-dioxane (1.0 mL) and the reaction mixture stirred at 110 °C for 16 hours. The reaction mixture was diluted with dichloromethane and water, and the layers separated. The aqueous layer was extracted with dichloromethane and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by prep HPLC (Waters Xbridge C185 pm OBD 19x 250 mm), eluting with 30 - 70 % acetonitrile in aqueous pH9 ammonium carbonate. The eluted fractions were concentrated and lyophilised to give (R)-3-(3-((1-methyl-1H-pyrazol-3-yl)methoxy)piperidin-1-yl)cinnoline (4.5 mg, 6 %) as a yellow oil.
[0619] 1H-NMR (400 MHz, DMSO-D6) 58.10 (d, J = 8.7 Hz, 1 H), 7.69 (d, J = 8.2 Hz, 1 H), 7.57-7.53 (m, 2H), 7.47-7.43 (m, 2H), 6.10 (d, 7 = 2.3 Hz, 1 H), 4.45 (s, 2H), 4.20-4.17 (m, 1 H), 3.97 (d, 7 = 13.3 Hz, 1H), 3.73 (s, 3H), 3.54-3.50 (m, 1H), 3.35-3.32 (m, 1H), 1.98 (dd, 7 = 10.8, 3.0 Hz, 1 H), 1.82-1.75 (m, 1 H), 1.57-1.45 (m, 2H).
[0620] UPLC_PH2_MECN_QC_V1: Rt 3.91 min, m / z 324.2 [M+H]+
[0621] UPLC_PH7_4_MECN_QC_V1: Rt4.64 min, m / z 324.2 [M+H]+
[0622] UPLC_PH9_MECN_QC_V1: Rt 4.14 min, m / z 324.3 [M+H]+
[0623] Example 25: (R)-2-Fluoro-3-(3-((1-methyl-1H-pyrazol-3-yl)methoxy)piperidin-1-yl)quinoxaline
[0624] (R)-2-Chloro-3-(3-((1-methyl-1 H-pyrazol-3-yl)methoxy)piperidin-1-yl)quinoxaline (42 mg, 0.117 mmol) and potassium fluoride (35 mg, 0.587 mmol) were dissolved in DMSO (1.2 mL) and the reaction mixture stirred at 90 °C for 3 hours. The reaction mixture was filtered and the crude product purified by prep HPLC (Waters Xbridge C185 pm OBD 19 x 250 mm), eluting with 40 - 75 % acetonitrile in aqueous pH9 ammonium carbonate. The eluted fractions were concentrated and lyophilised to give (R)-2-fluoro-3-(3-((1-methyl-1H-pyrazol-3-yl)methoxy)piperidin-1-yl)quinoxaline (30 mg, 75 %) as a white solid.
[0625] 1H NMR (400 MHz, DMSO-D6) 57.72 (dd, J = 8.2, 1.4 Hz, 2H), 7.66 - 7.60 (m, 1 H), 7.54 (d, 7 = 2.1 Hz, 1H), 7.52 -7.44 (m, 1H), 6.05 (d, 7 = 2.1 Hz, 1H), 4.42 (d, 7 = 2.7 Hz, 2H), 3.96 (dd, 7= 13.2, 3.1 Hz, 1H), 3.74 (s, 3H), 3.73-3.67 (m, 1H), 3.65-3.52 (m, 2H), 3.48 (dd,7= 13.2, 7.1 Hz, 1 H), 2.01 - 1.80 (m, 2H), 1.67 - 1.46 (m, 2H).
[0626] UPLC_PH2_MECN_QC_V1: Rt 5.02 min, m / z 342.4 [M+H]+
[0627] UPLC_PH7.4_MECN_QC_V1: Rt5.71 min, m / z 342.4 [M+H]+
[0628] UPLC_PH9_MECN_QC_V1: Rt 5.04 min, m / z 342.4 [M+H]+General Scheme 3 -Access to piperidine cores via pyridine reduction
[0629] Examples 26 and 27: (4R)-1-Methyl-4-(((1-(pyrrolidine-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidine-2-one Diastereomer A (Example 26) and Diastereomer B (Example 27)
[0630] Synthesis of (4R)-1 -[(1 R)-1 -(4-methoxyphenyl)ethyl]-4-(3-pyridyloxymethyl)pyrrolidine-2-one
[0631] ((R)-1-((R)-1-(4-Methoxyp enyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (2.00 g, 4.96 mmol), 3-hydroxypyridine (943 mg, 9.91 mmol), and potassium carbonate (1.37 g, 9.91 mmol) were dissolved in A / , A / -dimethylformamide (8.0 mL) and the reaction mixture stirred at 80 °C for one hour. The reaction mixture was diluted with water and ethyl acetate and the layers separated. The aqueous phase was extracted with ethyl acetate and the combined organics were dried, filtered, concentrated in vacuo and the crude product purified by flash column chromatography, eluting with 0-25 % ethanol in ethyl acetate to give (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((pyrrolid-3-yloxy)methyl)pyrrolidine-2-one (1.15 g, 71 %) as a pale-yellow oil.
[0632] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.54 mins, m / z 327.3 [M+H]+
[0633] (4R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-4-((piperidin-3-yloxy)methyl)pyrrolidine-2-one
[0634] Cyclooctadiene rhodium chloride dimer (174 mg, 0.352 mmol) and hypodiboric acid (3.16 g, 35.2 mmol) were dissolved in ethylene glycol (10 mL) under nitrogen before a solution of (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((pyrrolid-3-yloxy)methyl)pyrrolidine-2-one (1.15 g, 3.52 mmol) in ethylene glycol (10 mL) under nitrogen was added. The reaction mixture was stirred at 50 °C for 16 hours then cooled to room temperature. The reaction mixture was acidified with dilute aqueous hydrochloric acid, diluted with methanol and purified by catchrelease cartridge (Biotage SCX-2), washing with methanol and eluting with 2M ammonia inmethanol, and the solvent evaporated in vacuo. To the residue was added cyclooctadiene rhodium chloride dimer (174 mg, 0.352 mmol) and hypodiboric acid (3.16 g, 35.2 mmol). The reaction mixture was evacuated and backfilled with nitrogen before ethylene glycol (10 mL) was added and the reaction mixture stirred at 50 °C for 16 hours. The reaction mixture was acidified with dilute aqueous hydrochloric acid, diluted with methanol and purified by catchrelease cartridge (Biotage SCX-2), washing with methanol and eluting with 2M ammonia in methanol. The solvent was evaporated in vacuo to give (4R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((piperidin-3-yloxy)methyl)pyrrolidine-2-one (1.01 g, 86 %) as an orange oil.
[0635] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.43 mins, m / z 333.3 [M+H]+
[0636] (4R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one
[0637] (4R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((piperidin-3-yloxy)methyl)pyrrolidine-2-one (500 mg, 1.50 mmol), 2-chloroquinoxaline (495 mg, 3.01 mmol), and potassium carbonate (831 mg, 6.02 mmol) were dissolved in dimethyl sulfoxide (15 mL) and the reaction mixture stirred at 100 °C for one hour. The reaction mixture was diluted with dichloromethane and water and the layers separated. The aqueous layer was extracted thrice with a 3:2 mixture of chloroformisopropanol and the combined organic layers were dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 20 – 100 % ethyl acetate in isohexane to give (4R)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-(((1-(pyrrolidine-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidine-2-one (502 mg, 72 %) as a yellow oil.
[0638] UPLC_PH9_MECN_2.6MIN_V1: Rt 1.89 mins, m / z 461.4 [M+H]+
[0639] The following compounds were made by analogous methods to step 3 above, using General Method 1:
[0640] (4R)-4-(((1 -(Cinnolin-3-yl)piperidin-3-yl)oxy)methyl)-1 -((R)-1 -(4-methoxyphenyl)ethyl)pyrrolidin-2-one
[0641] To a mixture of 3-bromocinnoline (91 mg, 0.433 mmol), XantPhos Pd G3 (34 mg, 0.0361 mmol) and sodium tert-butoxide (69 mg, 0.722 mmol) was added a solution (4R)-1 -((R)- 1 -(4-methoxyphenyl)ethyl)-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (120 mg, 0.361 mmol) in dry 1,4-dioxane (3.0 mL). The reaction mixture was evacuated and backfilled with nitrogen three times and then sparged with nitrogen for 5mins. The reaction mixture was stirred at 110 °C for 40 mins. The reaction mixture was cooled to RT and partitioned between water (10 mL) and EtOAc (10 mL). The organic layer was washed with brine (aq. sat., 10 mL), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 15 % methanol in EtOAc to give (4R)-4-(((1-(cinnolin- 3-yl)piperidin-3-yl)oxy)methyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one (100 mg, 60 %) as a yellow residue.
[0642] UPLC_PH2_MECN_2.6MIN_V1: Rt 1.81 mins, m / z 461.5 [M+H]+
[0643] (4R)-1 -Methyl-4-[(1 -quinoxalin-2-yl-3-piperidyl)oxymethyl]pyrrolidin-2-one Diastereomer A and Diastereomer B
[0644] (4R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one (502 mg, 1.09 mmol) was dissolved in TFA (5.0 mL) and the reaction mixture stirred at 80 °C for 2 hours. The solvent was evaporated in vacuo, resuspended in dichloromethane and sodium carbonate (aq., sat.) and the layers separated. The aqueous layerwas extracted with dichloromethane and the combined organic layers dried, filtered, and concentrated in vacuo. The residue was resuspended in A / , A / -dimethylformamide (5.0 mL) and the mixture cooled to 0 °C before sodium hydride (60% dispersion in oil, 174 mg, 4.36 mmol) was added portion-wise. The reaction mixture was stirred for 10 minutes, iodomethane (0.34 mL, 5.45 mmol) was added and the reaction mixture stirred at room temperature for one hour. The reaction mixture was diluted with dichloromethane and water and the layers separated. The aqueous layerwas extracted with dichloromethane and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 50 - 100 % ethyl acetate in isohexane to give a mixture of the two diastereoisomers (170 mg) as a yellow oil. The mixture was then purified by chiral HPLC to yield the two individual diastereoisomers:
[0645] Diastereomer A: (4R)-1-Methyl-4-[(1-quinoxalin-2-yl-3-piperidyl)oxymethyl]pyrrolidin-2-one (51 mg, 14 %) as a yellow oil.
[0646] 1H-NMR (400 MHz, DMSO-D6) 58.80 (s, 1 H), 7.75 (d, J = 8.2 Hz, 1 H), 7.55-7.50 (m, 2H), 7.36-7.29 (m, 1 H), 4.02 (dd, J = 13.3, 2.7 Hz, 1 H), 3.81 -3.75 (m, 1 H), 3.66-3.62 (m, 1 H), 3.58 (q, 7 = 6.7 Hz, 1H), 3.51-3.41 (m, 2H), 3.34 (dd, J = 9.2, 7.3 Hz, 1H), 3.17 (dd, 7 = 9.6, 8.2 Hz, 1H), 2.85 (q, 7 = 5.0 Hz, 1 H), 2.51 (s, 3H), 2.42-2.34 (m, 1 H), 2.19 (dd, 7 = 16.5, 9.2 Hz, 1 H), 1.92-1.86 (m, 2H), 1.78-1.70 (m, 1H), 1.58 (tt, 7= 12.0, 3.9 Hz, 1 H), 1.49-1.40 (m, 1 H).
[0647] UPLC_PH2_MECN_QC_V1: Rt 3.97 min, m / z 341.3 [M+H]+
[0648] UPLC_PH7_4_MECN_QC_V1: Rt4.58 min, m / z 341.2 [M+H]+
[0649] UPLC_PH9_MECN_QC_V1: Rt 4.11 min, m / z 341.3 [M+H]+
[0650] Diastereomer B (4R)-1-Methyl-4-[(1-quinoxalin-2-yl-3-piperidyl)oxymethyl]pyrrolidin-2-one (54 mg, 15 %,) as a yellow oil.
[0651] 1H-NMR (400 MHz, DMSO-D6) 58.79 (s, 1 H), 7.75 (d, 7 = 8.2 Hz, 1 H), 7.53-7.52 (m, 2H), 7.34-7.30 (m, 1 H), 3.97 (dd, 7 = 13.5, 3.0 Hz, 1 H), 3.79-3.73 (m, 1 H), 3.70-3.62 (m, 2H), 3.47-3.35 (m, 3H), 3.23-3.17 (m, 1 H), 2.85 (q, 7 = 5.0 Hz, 1 H), 2.49 (s, 3H), 2.44-2.36 (m, 1 H), 2.18 (dd, 7= 16.5, 9.2 Hz, 1H), 1.91 -1.84 (m, 2H), 1.79-1.71 (m, 1 H), 1.59 (tt, 7 = 11.9, 3.8 Hz, 1H), 1.49-1.41 (m, 1H).
[0652] UPLC_PH2_MECN_QC_V1: Rt 3.98 min, m / z 341.3 [M+H]+
[0653] UPLC_PH7_4_MECN_QC_V1: Rt4.58 min, m / z 341.2 [M+H]+
[0654] UPLC_PH9_MECN_QC_V1: Rt 4.11 min, m / z 341.3 [M+H]+
[0655] The following compounds were made analogous to steps 4 and 5 above, using General Methods 4 and 5:
[0656] Examples 32 and 33: (4S)-4-(((1-(Cinnolin-3-yl)piperidin-3-yl)oxy)methyl)-1-methylpyrrolidin-2-one Diastereomer A (Example 32) and Diastereomer B (Example 33)
[0657] To a mixture of 3-bromocinnoline (47 mg, 0.226 mmol), XantPhos Pd G3 (18 mg, 0.0188 mmol) and sodium tert-butoxide (36 mg, 0.377 mmol) was added a solution of (4S)-1 -methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (40 mg, 0.188 mmol) in dry 1,4-dioxane (0.50 mL). The reaction mixture was evacuated and backfilled with nitrogen three times and then sparged with nitrogen for 5mins. The reaction mixture was stirred at 110 °C for 40 mins. The reaction mixture was cooled to RT, diluted with water (10 mL) and DCM (2 mL). The organics were separated and the aqueous layer was back extracted with DCM (2x2 mL). The combined organic extracts were washed with brine (aq. sat., 10 mL), passed through a phase separatorand concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 0 – 15 % methanol in EtOAc to provide the partially purified products. The products were further purified by preparative HPLC (pH2) to provide the two individual diastereoisomers:
[0658] Diastereomer A (Example 32) (4S)-4-(((1-(Cinnolin-3-yl)piperidin-3-yl)oxy)methyl)-1-methylpyrrolidin-2-one (12.4 mg, 19 %) as a brown gum.
[0659] 1H-NMR (400 MHz, DMSO-D6) 58.16-8.13 (m, 1 H), 7.73 (d, J = 8.2 Hz, 1H), 7.61-7.57 (m, 1H), 7.51 -7.47 (m, 1H), 7.46 (s, 1 H), 4.21 (dd,7= 12.6, 3.0 Hz, 1H), 3.96 (ddd, J = 12.8, 5.3, 3.4 Hz, 1 H), 3.53-3.46 (m, 2H), 3.44-3.36 (m, 3H), 3.29 (dd, J = 9.6, 8.2 Hz, 1 H), 2.95 (dd, J = 9.8, 5.3 Hz, 1 H), 2.61 (s, 3H), 2.48-2.41 (partially obscured, m, 1 H), 2.27 (dd, J = 16.7, 9.4 Hz, 1 H), 2.02-1.93 (m, 2H), 1.87-1.79 (m, 1 H), 1.61-1.49 (m, 2H).
[0660] UPLC_PH9_MECN_QC_V1: Rt 4.04 min, m / z 341.4 [M+H]+
[0661] UPLC_PH7.4_MECN_QC_V1: Rt4.52 min, m / z 341.4 [M+H]+
[0662] UPLC_PH2_MECN_QC_V1: Rt 3.79 min, m / z 341.4 [M+H]+
[0663] Diastereomer B (Example 33) (4S)-4-(((1-(Cinnolin-3-yl)piperidin-3-yl)oxy)methyl)-1-methylpyrrolidin-2-one (12.5 mg, 19 %) as a brown gum.
[0664] 1H-NMR (400 MHz, DMSO-D6) 58.15-8.13 (m, 1 H), 7.73 (d, J = 8.2 Hz, 1H), 7.61-7.57 (m, 1 H), 7.51 -7.47 (m, 1 H), 7.46 (s, 1 H), 4.21-4.15 (m, 1 H), 3.95-3.90 (m, 1 H), 3.50-3.37 (m, 5H), 3.30 (dd, J = 9.8, 8.5 Hz, 1 H), 2.93 (dd, J = 9.8, 5.3 Hz, 1 H), 2.58 (s, 3H), 2.48-2.42 (m, 1 H), 2.26 (dd, J= 16.7, 9.4 Hz, 1H), 2.02-1.98 (m, 1H), 1.93 (dd,7= 16.7, 6.2 Hz, 1 H), 1.86-1.79 (m, 1 H), 1.62-1.49 (m, 2H).
[0665] UPLC_PH9_MECN_QC_V1: Rt 4.05 min, m / z 341.4 [M+H]+
[0666] UPLC_PH7.4_MECN_QC_V1: Rt 4.53 min, m / z 341.4 [M+H]+
[0667] UPLC_PH2_MECN_QC_V1: Rt 3.80 min, m / z 341.4 [M+H]+Syntheses of tosylates
[0668] ((R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate and ((S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate
[0669] Methyl (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate and methyl (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate
[0670] A solution of dimethyl itaconate (10.5 g, 66.1 mmol) and (R)-1-(4-methoxyphenyl)ethan-1 -amine (9.80 mL, 66.1 mmol) in methanol (63 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, resuspended in toluene (42 mL) and p-toluenesulfonic acid monohydrate (1.26 g, 6.61 mmol) was added and the reaction mixture stirred at reflux for 1.5 hours. The reaction mixture was concentrated under reduced pressure and the crude product purified by flash column chromatography eluting with 0 - 100 % EtOAc-isohexane to provide:
[0671] Methyl (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (8.44 g, 46 %) as a pale-yellow oil
[0672] 1H-NMR (400 MHz, Chloroform-D) 67.24-7.20 (m, 2H), 6.88-6.84 (m, 2H), 5.44 (q, J = 7.0 Hz, 1 H), 3.79 (s, 3H), 3.71 (s, 3H), 3.52 (dd, J = 9.6, 6.4 Hz, 1 H), 3.17 (t, J = 9.4 Hz, 1 H), 3.12- 3.04 (m, 1 H), 2.77-2.62 (m, 2H), 1.50 (d, J = 7.6 Hz, 3H).
[0673] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.61 mins., m / z 278.2 [M+H]+
[0674] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.70 mins., m / z 278.2 [M+H]+and:
[0675] Methyl (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (7.13 g, 39 %) as a pale-yellow oil
[0676] 1H-NMR (400 MHz, Chloroform-D) 57.22-7.19 (m, 2H), 6.88-6.84 (m, 2H), 5.45 (q, J = 7.2 Hz, 1 H), 3.80 (s, 3H), 3.65 (s, 3H), 3.51 (dd, J = 9.4, 8.0 Hz, 1 H), 3.22-3.11 (m, 2H), 2.75-2.63 (m, 2H), 1.50 (d, J = 6.9 Hz, 3H).
[0677] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.60 mins., m / z 278.2 [M+H]+
[0678] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.68 mins., m / z 278.2 [M+H]+
[0679] Synthesis of ((R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate
[0681] Using methyl (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (7.38 g, 26.6 mmol) with GM6, gave a crude sample of (R)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one which was used directly in the next step without further purification.
[0682] 1H-NMR (400 MHz, Chloroform-D) 67.24-7.20 (m, 2H), 6.88-6.84 (m, 2H), 5.44 (q, J = 7.0 Hz, 1H), 3.80 (s, 3H), 3.65 (dd,7= 10.5, 6.0 Hz, 1H), 3.57 (dd,7= 10.5, 7.3 Hz, 1H), 3.17 (dd, J = 9.8, 5.3 Hz, 1 H), 3.08 (dd, J = 9.8, 8.0 Hz, 1 H), 2.53 (dd, J = 16.3, 8.9 Hz, 1 H), 2.48-2.37 (m, 1 H), 2.26 (dd, J = 16.5, 6.0 Hz, 1 H), 1.49 (d, J = 7.3 Hz, 3H).
[0683] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.37 mins., m / z 250.3 [M+H]+
[0684] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.35 mins., m / z 250.3 [M+H]+
[0685] ((R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate
[0686] Using (R)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one and TsCl (1.05 eq) in GM5 with purification by flash column chromatography eluting with 0-80 % EtOAc-isohexane gave ((R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate as a clear orange oil (4.59 g, 43 %).
[0687] 1H-NMR (400 MHz, Chloroform-D) 67.78-7.76 (m, 2H), 7.36 (d, J = 7.8 Hz, 2H), 7.20-7.16 (m, 2H), 6.87-6.83 (m, 2H), 5.40 (q, J = 7.0 Hz, 1 H), 3.97 (dd, J = 9.8, 5.3 Hz, 1 H), 3.91 (dd, J = 9.6, 7.8 Hz, 1 H), 3.80 (s, 3H), 3.09-3.02 (m, 2H), 2.62-2.48 (m, 2H), 2.46 (s, 3H), 2.10 (dd, J = 16.3, 5.7 Hz, 1H), 1.41 (d, J = 7.3 Hz, 3H).
[0688] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.83 mins., m / z 404.3 [M+H]+
[0689] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.82 mins., m / z 404.3 [M+H]+
[0690] (R)-(1 -Methyl-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate
[0691] ((R)-1-((R)-1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (2.80 g, 6.25 mmol) was dissolved in TFA (10 mL) and the reaction mixture stirred at 80 °C for one hour. The reaction mixture was concentrated in vacuo, diluted with DCM and sodium bicarbonate solution, and the layers separated. The aqueous layer was extracted with DCM, and the combined organic layers were dried, filtered, concentrated in vacuo and resuspended in N, N-dimethylformamide (10 mL). The solution was cooled to 0 °C before sodium hydride (60% dispersion in oil, 0.50 g, 12.5 mmol) was added and the reaction mixture stirred for 5 minutes at 0 °C. lodomethane (0.78 mL, 12.5 mmol) was added and the reaction mixture was stirred at room temperature for one hour. The reaction mixture was quenched with water, diluted with DCM and the layers separated. The aqueous layer was extracted with DCM and the combined organic layers dried, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography, eluting with 0 - 50 % ethyl acetate in isohexane to give (R)-(1-methyl-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (1.40 g, 79 %) as a colourless oil.
[0692] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.48 mins., m / z 284.1 [M+H]+
[0693] Synthesis of ((S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate
[0694] (S)-4-(Hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one
[0695] Using methyl (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate (7.12 g, 25.7 mmol) with GM6, gave a crude sample of (S)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one which was used directly in the next step without further purification.
[0696] 1H-NMR (400 MHz, Chloroform-D) δ 7.23-7.20 (m, 2H), 6.88-6.84 (m, 2H), 5.44 (q, J = 7.2 Hz, 1 H), 3.79 (s, 3H), 3.51 (dd, J = 10.5, 6.0 Hz, 1 H), 3.44-3.39 (m, 2H), 2.79 (dd, 7 = 10.1, 5.0 Hz, 1 H), 2.58 (dd, 7 = 16.3, 8.9 Hz, 1 H), 2.53-2.45 (m, 1 H), 2.23 (dd, 7 = 16.5, 5.0 Hz, 1 H), 1.49 (d, 7 = 7.3 Hz, 3H).
[0697] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.40 mins., m / z 250.3 [M+H]+
[0698] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.47 mins., m / z 250.3 [M+H]+
[0699] ((S)-1 -((R)-1 -(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate
[0700] Using (S)-4-(hydroxymethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one and TsCl (1.05 eq) in GM5 with purification by flash column chromatography eluting with 0 -80 % EtOAc-isohexane gave ((S)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (9.08 g, 85 %) as a colourless oil.
[0701] 1H-NMR (400 MHz, Chloroform-D) δ 7.69-7.66 (m, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.18-7.14 (m, 2H), 6.87-6.83 (m, 2H), 5.40 (q, J = 7.2 Hz, 1 H), 3.85 (dd, J = 9.8, 5.7 Hz, 1 H), 3.82 (s, 3H), 3.78 (dd, J = 9.8, 7.6 Hz, 1H), 3.42-3.37 (m, 1H), 2.71-2.59 (m, 2H), 2.53 (dd, J = 16.5, 9.2 Hz, 1 H), 2.45 (s, 3H), 2.08 (dd, 7= 17.1, 5.8 Hz, 1 H), 1.46 (d, J = 7.3 Hz, 3H).
[0702] UPLC_PH2_MECN_2.6MIN_V1; Rt 1.81 mins., m / z 404.5 [M+H]+
[0703] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.80 mins., m / z 404.5 [+H]+
[0704] Synthesis of (4S)-1-methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one
[0705] (S)-1-((R)-1-(4-Methoxyphenyl)ethyl)-4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one
[0706] ((S)-1 -((R)-1 -(4-Methoxyphenyl)ethyl)-5-oxopyrrolidin-3-yl)methyl 4-methylbenzenesulfonate (1.00 g, 2.48 mmol), potassium carbonate (754 mg, 5.45 mmol) and 3-hydroxypyridine (259 mg, 2.73 mmol) were dissolved in N, N-dimethylformamide (9.9 mL). The reaction mixture was stirred at 80 °C for 1 hour. The reaction mixture was diluted with EtOAc (20 mL), washed with water (50 mL) and the aqueous phase back extracted with EtOAc (2 x 10 mL). The combined organics were washed with brine (aq. sat., 50 mL), passed through a phase separator, concentrated in vacuo and the crude product purified by flash column chromatography, eluting with 0 - 10% EtOAc in isohexane to provide (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one (680 mg, 84 %) as an off-white solid.
[0707] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.51 mins., m / z 327.4 [M+H]+
[0708] (4S)-1 -((R)-1 -(4-methoxyphenyl)ethyl)-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one
[0709] To a MW vial was added hypodiboric acid (1.30 g, 14.5 mmol). The vessel was evacuated and filled with nitrogen (x3) before the addition of a solution of (S)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((pyridin-3-yloxy)methyl)pyrrolidin-2-one (677 mg, 2.07 mmol) in ethylene glycol (6.9 mL). The vessel was evacuated and filled with nitrogen before the addition of cyclooctadiene rhodium chloride dimer (205 mg, 0.415 mmol). The vessel was evacuated and filled with nitrogen a final time. The reaction mixture was stirred at 50 °C for 16 hours. The reaction mixture was filtered through a celite cartridge then diluted with MeOH and the crude product purified by catch-release cartridge (Biotage SCX-2), washing with methanol and eluting with 2M ammonia in methanol to give (4S)-1-((R)-1-(4-methoxyphenyl)ethyl)-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (542 mg, 79 %) as a yellow oil.
[0710] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.60 mins., m / z 333.4 [M+H]+
[0711] (4S)-4-((Piperidin-3-yloxy)methyl)pyrrolidin-2-one
[0712] To (4S)-1-[(1 R)-1-(4-methoxyphenyl)ethyl]-4-(3-piperidyloxymethyl)pyrrolidin-2-one (542 mg, 1.63 mmol) was added TFA(8.2 mL) and the reaction mixture was stirred at 80 °C until reaction completion. The reaction mixture was concentrated in vacuo and the crude product purified by catch-release cartridge (Biotage SCX-2), washingwith methanol and eluting with 2M ammonia in methanol to give (4S)-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (345 mg, > 100 %) as a yellow gum.
[0713] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.04 mins., m / z 243.3 [M+H]+
[0714] tert-Butyl 3-(((S)-5-oxopyrrolidin-3-yl)methoxy)piperidine-1 -carboxylate
[0715] A solution of (4S)-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (323 mg, 1.63 mmol) and triethylamine (0.45 mL, 3.26 mmol) in dry DCM (4.2 mL) was cooled to -10 °C and a solution of di-tert-butyl dicarbonate (0.37 mL, 1.63 mmol) in dry DCM (1.4 mL) was added dropwise over 5 mins. The reaction mixture was then stirred at -10 °C and slowly warmed to room temperature overnight. The reaction mixture was diluted with water (10 mL)and extracted with DCM (3x 10 mL). The combined organic extracts were washed with brine (aq. sat.), dried (Na2SO4), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 10 % MeOH in EtOAc to provide tert-butyl 3-(((S)-5-oxopyrrolidin-3-yl)methoxy)piperidine-1 -carboxylate (316 mg, 65 %) as a clear colourless gum.
[0716] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.50 mins., m / z 321.4 [M+Na]+
[0717] tert-Butyl 3-(((S)-1-methyl-5-oxopyrrolidin-3-yl)methoxy)piperidine-1 -carboxylate
[0718] To a solution of tert-butyl 3-(((S)-5-oxopyrrolidin-3-yl)methoxy)piperidine-1-carboxylate (311 mg, 1.04 mmol) in dry N, N-dimethylformamide (2.6 mL) at -10 °C was added sodium hydride (60% dispersion in oil, 167 mg, 4.17 mmol) and the reaction mixture was stirred for 15 mins at -10 °C. lodomethane (0.26 mL, 4.17 mmol) was added dropwise over 1 minute and the reaction mixture stirred at -10 °C until completion. The reaction mixture was quenched with NH4Cl (aq. sat.) and then diluted with water (20 mL) and EtOAc (10 mL). The organics were separated and the aqueous phase back extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (aq. sat., 20 mL), dried (Na2SO4), passed through a phase separator and concentrated in vacuo. The crude product was purified by flash column chromatography eluting with 0 - 5 % MeOH in EtOAc to provide tert-butyl 3-(((S)-1-methyl-5-oxopyrrolidin-3-yl)methoxy)piperidine-1 -carboxylate (286 mg, 88 %) as a pale-yellow oil.
[0719] UPLC_PH9_MECN_2.6MIN_V1; Rt 1.58 mins., m / z 213.3 [M-Boc+H]+
[0720] (4S)-1-Methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one
[0721] To a solution of tert-butyl 3-(((S)-1-methyl-5-oxopyrrolidin-3-yl)methoxy)piperidine-1-carboxylate (281 mg, 0.898 mmol) in 1,4-dioxane (1.9 mL) at room temperature was added dropwise over 2 minutes hydrochloric acid (4M in dioxane, 2.2 mL, 8.98 mmol). The reaction mixture was stirred at room temperature for 45 mins. The reaction mixture was concentrated in vacuo, redissolved in MeOH and the crude product purified by catch-release cartridge (Biotage SCX-2), washing with methanol and eluting with 2M ammonia in methanol to give (4S)-1 -methyl-4-((piperidin-3-yloxy)methyl)pyrrolidin-2-one (179 mg, 94 %) as a pale-yellow oil.
[0722] UPLC_PH9_MECN_2.6MIN_V1; Rt 0.96 mins., m / z 213.2 [M+H]+Step 1General Scheme 4 - Alkylation
[0723] Example 34 and 35: (4S)-1-Methyl-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one Diastereomer A (Example 34) and Diastereomer B (Example 35)
[0724] To a mixture of potassium carbonate (52 mg, 0.377 mmol) and 2-chloroquinoxaline (34 mg, 0.207 mmol) was added a solution of (4S)-1-methyl-4-(3-piperidyloxymethyl)pyrrolidin-2-one (40 mg, 0.188 mmol) in dry N, N-dimethylformamide (0.63 mL) and the reaction mixture was stirred at 100 °C for 20 mins. The reaction mixture was cooled to RT and the mixture diluted with water (10 mL) and DCM (2 mL). The organic layerwas separated, and the aqueous layer was back extracted with DCM (2 x 2 mL). The combined organic extracts were washed with brine (aq. sat., 10 mL), passed through a phase separator and concentrated in vacuo. The crude products were purified by flash column chromatography, eluting with 0 - 15% methanol in EtOAc. The products were further purifiedby prep HPLC (pH2) and lyophilised to give a sample as a mixture of the two diastereomers. The crude products were purified by chiral HPLC to yield the two individual diastereoisomers:
[0725] Diastereomer A (Example 34) (4S)-1-Methyl-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one (17.4 mg, 27 %) as a yellow gum.
[0726] 1H-NMR (400 MHz, DMSO-D6) 6 8.84 (s, 1H), 7.80-7.78 (m, 1H), 7.58-7.54 (m, 2H), 7.39-7.34 (m, 1 H), 4.01 (dd, J = 13.4, 2.9 Hz, 1 H), 3.82-3.60 (m, 3H), 3.53-3.38 (m, 3H), 3.25 (dd, J = 9.6, 8.2 Hz, 1 H), 2.88 (dd, J = 9.8, 5.3 Hz, 1 H), 2.52 (s, 3H), 2.47-2.38 (m, 1 H), 2.22 (dd, J = 16.5, 9.2 Hz, 1H), 1.96-1.87 (m, 2H), 1.83-1.74 (m, 1 H), 1.67-1.59 (m, 1 H), 1.53-1.44 (m, 1 H).
[0727] UPLC_PH9_MECN_QC_V1: Rt 4.22 min, m / z 341.4 [M+H]+
[0728] UPLC_PH7.4_MECN_QC_V1: Rt 4.72 min, m / z 341.4 [M+H]+
[0729] UPLC_PH2_MECN_QC_V1: Rt 4.11 min, m / z 341.4 [M+H]+
[0730] Diastereomer B (Example 35) (4S)-1-Methyl-4-(((1-(quinoxalin-2-yl)piperidin-3-yl)oxy)methyl)pyrrolidin-2-one (16.1 mg, 25 %) as a yellow gum.
[0731] 1H-NMR (400 MHz, DMSO-D6) δ 8.84 (s, 1H), 7.79 (d, J = 8.2 Hz, 1 H), 7.59-7.54 (m, 2H), 7.40-7.33 (m, 1H), 4.06 (dd,7 = 13.3, 2.7 Hz, 1H), 3.82 (ddd,7= 13.2, 7.0, 3.8 Hz, 1H), 3.71-3.60 (m, 2H), 3.53-3.44 (m, 2H), 3.38 (dd, J = 8.9, 7.6 Hz, 1H), 3.21 (dd, J = 10.1, 8.2 Hz, 1H), 2.89 (dd, J = 9.6, 5.5 Hz, 1 H), 2.55 (s, 3H), 2.46-2.37 (m, 1 H), 2.23 (dd, J = 16.5, 9.2 Hz, 1 H), 1.96-1.90 (m, 2H), 1.83-1.74 (m, 1 H), 1.66-1.58 (m, 1 H), 1.53-1.43 (m, 1 H).
[0732] UPLC_PH9_MECN_QC_V1: Rt 4.21 min, m / z 341.4 [M+H]+
[0733] UPLC_PH7.4_MECN_QC_V1: Rt 4.72 min, m / z 341.4 [M+H]+
[0734] UPLC_PH2_MECN_QC_V1: Rt 4.1 min, m / z 341.4 [M+H]+
[0735] The following compounds were made analogous to step 1 above, using General Method 1:Biological Assays
Claims
CLAIMS1. A compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof:, 5- to 6-membered heteroaryl, and -C(O)NR1aR1b;whereinR1aand R1bare each independently selected from: H, C1-6alkyl, and C1-6haloalkyl; Z1and Z4are each nitrogen, andZ2, Z3, Z5, and Z6are independently selected from: a bond, carbon, nitrogen, and oxygen;-membered heteroaryl are optionally substituted by one or more R2;R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR2a, -C(O)R2a, -OC(O)R2a, and -C(O)OR2a;X1is selected from: a bond, -O-, -NR3-, and -S(O)X-,wherein R3is independently selected from: deuterium, H, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-C1-6alkyl;L is selected from: C1-8alkylene and -C(O)-;wherein said C1-8alkylene is optionally substituted by one or more R4;R4is selected from: deuterium, halo, -CN, -NO2, -NR4aR4b, -OR4a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR4a, -C(O)R4a, -OC(O)R4a, -C(O)OR4a;X2is selected from: -O-, and -S(O)X-;Ring A is a 5- or 6-membered heterocycloalkyl or 5- or 6-membered heterocycloalkenyl, wherein one of A1and A2is selected from a bond, carbon and nitrogen and the other of A1and A2is carbon or nitrogen, and A3is carbon or nitrogen;wherein Ring A is optionally substituted by one or more R5;R5is selected from: deuterium, halo, -CN, -NO2, -NR5aR5b, -OR5a, =O, C1_6alkyl, C1_6haloalkyl, C2-6alkenyl, C2.6alkynyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR5a, -C(O)R5a, -OC(O)R5a, and -C(O)OR5a;the groupR6is selected from: deuterium, halo, -CN, -NO2, -NR6aR6b, -OR6a, C1_6alkyl, C1_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3.6cycloalkyl, 4-membered heterocycloalkyl, -S(O)xR6a, -C(O)R6a, -OC(O)R6a, and -C(O)OR6a;Ring C is selected from: 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, phenyl, and 5- or 6-membered heteroaryl,wherein said 4- to 7-membered heterocycloalkyl, 4- to 7-membered cycloalkyl, 5- to 7-membered cycloalkenyl, and 5- to 7-membered heterocycloalkenyl are optionally substituted by one or more R7, and said phenyl and 5- or 6-membered heteroaryl are optionally substituted by one or more R8;R7is selected from: deuterium, halo, -CN, -NO2, -NR7aR7b, -OR7a, =O, Ci_6alkyl, Ci_6haloalkyl, C2-6 alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR7a, -C(O)R7a, -OC(O)R7a, and -C(O)OR7a;R8is selected from: deuterium, halo, -CN, -NO2, -NR8aR8b, -OR8a, Ci_6alkyl, Ci_6haloalkyl, C2.6alkenyl, C2.6alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, -S(O)xR8a, -C(O)R8a, -OC(O)R8a, and -C(O)OR8a;R2a, R4a, R5a, R6a, R7a, and R8aare each independently selected from: deuterium, H, C1-6alkyl, C1-6 haloalkyl, C3-6cycloalkyl, and 4- to 6-membered heterocycloalkyl;R2b, R4b, R5b, R6b, R7b, and R8bare each independently selected from: deuterium, H, C1-6alkyl, C1-6 haloalkyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl, and -C(O)-C1-6alkyl;or wherein, at each occurrence, R2aand R2b, R4aand R4b, R5aand R5b, R6aand R6b, R7aand R7b, or R8aand R8b, together with the nitrogen atom to which they are attached, may form a 4-6-membered heterocycloalkyl ring;each x is independently 0, 1, or 2;wherein any of the aforementioned alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, phenyl, or heteroaryl groups is optionally substituted, where chemically possible, by one or more substituents independently at each occurrence selected from thegroup consisting of: C1-6alkyl, C1_6alkyl-ORa, deuterium, oxo, halo, nitro, cyano, NRaRb, ORa, SRa, CO2Ra, C(O)Ra, CONRaRa, S(O)Ra, and S(O)2Ra; wherein Rais independently at each occurrence selected from H, and C1-4 alkyl; and Rbis independently at each occurrence selected from H, C1-4alkyl, C(O)-C1-4alkyl and S(O)2-C1-4alkyl; andwherein the compound according to formula (I) is not a compound selected from List A:List A2. The compound accordingto claim 1, or a pharmaceutically acceptable salt and / orsolvate thereof, wherein, optionally substituted by one or more R2.
3. The compound accordingto claim 1 or claim 2, wherein R1is selected from, optionally wherein R1is substituted with one or more R2.
4. The compound according to claim 1, wherein R1is a 5- to 6-membered heteroaryl, optionally substituted by one or more R2.
5. The compound accordingto anyone of claims 1 to 4, wherein R2is selected from: deuterium, halo, -CN, -NO2, -NR2aR2b, -OR2a, =O, C1-6alkyl, C1-6haloalkyl.
6. The compound according to any one of claims 1 to 5, wherein L is C1_3alkylene, optionally substituted by one or more independently selected R4.
7. The compound accordingto anyone of claims 1 to 6, wherein X1is a bond.
8. The compound accordingto any one of claims 1 to 7, wherein X2is: -O-.
9. The compound accordingto anyone of claims 1 to 8, wherein -X1-L-X2- is -CH2-O-.
10. The compound accordingto anyone of claims 1 to 9, wherein Ring A is:wherein n is an integer selected from 0 to 6, optionally wherein Ring A is11. The compound accordingto anyone of claims 1 to 9, Ring A is a 5 memberedheterocycloalkyl with the formula:
12. The compound accordingto anyone of claims 1 to 11, wherein the groupis selected from:
13. The compound according to anyone of claims 1 to 12, wherein the groupby one or more R7or R8.
14. The compound according to anyone of claims 1 to 11, wherein the groupis selected from:Ring B is substituted by one or more R6and, further optionally wherein Ring C is substituted by one or more R7or R8.
15. The compound according to claim 1, wherein the compound is a compound of formula (II), ora pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2; andRing A is optionally substituted by one or more R5.
16. The compound according to claim 1, wherein the compound is a compound of formula (III), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthe [structure] group is optionally substituted by one or more R².
17. The compound according to claim 1, wherein the compound is a compound of formula (IV), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2; andRing A is optionally substituted by one or more R5.
18. The compound according to claim 1, wherein the compound is a compound of formula (V), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is selected from:-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6; andRingC is optionally substituted by one or more R8.
19. The compound according to claim 1, wherein the compound is a compound of formula (VI), or a pharmaceutically acceptable salt and / or solvate thereof:whereinthegroup is optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6; andRing C is optionally substituted by one or more R8.
20. The compound accordingto claim 1, wherein the compound is a compound of formula (IX), or a pharmaceutically acceptable salt and / or solvate thereof:whereinR1is a 5- to 6-membered heteroaryl, optionally substituted by one or more R2;Ring A is optionally substituted by one or more R5;Ring B is optionally substituted by R6; andRing C is optionally substituted by one or more R8.
21. A compound according to claim 1, wherein the compound is selected from Compound List 1 in the description, or a pharmaceutically acceptable salt and / or solvate thereof.
22. A pharmaceutical composition comprising a compound accordingto anyone of claims 1 to 21, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, and a pharmaceutically acceptable excipient.
23. A compound accordingto anyone of claims 1 to 21, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use as a medicament.
24. A compound accordingto anyone of claims 1 to 21, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder associated with dysregulation of tropomyosin receptor kinase B (TrkB or NTRK2).
25. A compound accordingto anyone of claims 1 to 21, except that the compounds of List A are not excluded, or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of a disease or medical disorder selected from: autism spectrum disorder (ASD), intellectual disability, Rett Syndrome, Down’s Syndrome (DS), Major Depressive Disorder (MDD), Bipolar Disorder (BD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), NeuroAIDS (HIV-associatedneurocognitive disorder), Fetal Alcohol Spectrum Disorder (FASD), Hypoxia-Ischemic Encephalopathy (HIE), and Traumatic Brain Injury (TBI);optionally wherein the disease or medical disorder is selected from: Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Bipolar Disorder (BD) and Traumatic Brain Injury (TBI).
